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INTRODUCTION 
Neonatal encephalopathy following perinatal hypoxia and 
ischemia is a major cause of neonatal morbidity and mortality 
globally. In resource rich countries, the incidence of severe perinatal 
asphyxia (causing death or severe neurological impairment) is about 
1/1000 live births. [1]  
In developing countries, rates of birth asphyxia are several folds 
higher, ranging from 4.6 per1000 in Cape Town [7] to 26 per 1000 in 
Nigeria [8] and fatality rates may be 40% or higher [9]. Data from 
hospital-based studies suggest an incidence of 5–10/1000 live births 
[2, 3, 4]. In India, the National Neonatal Perinatal Database reported 
an incidence of 5% of intramural live births among studies conducted 
in 16 medical institutes [5]. As per World Health Organization (WHO) 
statistics, between four and nine million newborns develop birth 
asphyxia each year. Of those, an estimated 1.2 million die and at least 
the same number develop severe consequences, such as epilepsy, 
cerebral palsy, and developmental delay. [6]  
Encephalopathy occurs in 50% to 60% patients with severe 
perinatal asphyxia [7]. Moderate/severe hypoxic ischemic 
encephalopathy (HIE) causes significant morbidity and death in the 
neonatal period and permanent neurodevelopmental handicaps among 
survivors [8] 
Among neonates with moderate HIE, 20% to 37% die and 30% 
to 40% develop neurodeficits, whereas 50% of patients with severe 
HIE die and almost all survivors develop neurological deficits [9, 10]. 
Neurological abnormality at discharge is a strong predictor of long 
term neurodevelopment delay [11]. 
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Thus perinatal asphyxia and hypoxic encephalopathy is a major 
cause for neonatal morbidity and mortality. The neurological sequale 
that follows is a burden to the family & society and there is an urgent 
need to improve its management. As per WHO, the disability 
produced by asphyxial injury and its sequelae exceed those due to all 
childhood conditions preventable by immunization[12]. 
Primary neuronal injury occurs during the period of hypoxia 
and ischemia and stops with resuscitative measures. Secondary 
neuronal injury continues for hours to days even after the reversal of 
asphyxial event, and excitotoxicity mediated by glutamate is one of 
the important mechanisms responsible for this type of injury [13]. 
This secondary phase of neuronal injury may last as long as 72 hours 
[11, 13, 15,] 
During asphyxia there is excessive release and reduced 
uptake of glutamic acid, predominant excitatory neurotransmitter 
in brain. Glutamate acts on the N-methyl-D-aspartate (NMDA) 
receptor, a postsynaptic ion channel in the brain. Increased 
concentration of glutamate opens up NMDA channels resulting in 
excessive influx of calcium into neuronal cells leading to neuronal 
injury [11] 
Magnesium is a naturally occurring NMDA receptor 
antagonist that blocks the influx of calcium at the neuronal ion 
channel level [14].  Neuronal depolarisation that occurs during 
asphyxia overcomes this block. Increasing the concentration of 
magnesium in the extracellular fluid of neuronal cells will restore 
the block [15]. 
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Thus magnesium can be used to prevent the excitotoxic injury 
that occurs during the initial hours following the primary neuronal 
injury. Studies  regarding the effects of magnesium after simulated 
hypoxic-ischemic insults in several animal models revealed beneficial 
effects in some studies [16,17,18] and no effect in some [ 19,20]. 
Some authors have suggested a reduction of cerebral palsy following 
the use of magnesium sulphate during pregnancy [21, 22] whereas 
others have not been able to show this [23, 24, 25].  Two prospective 
human studies have shown improved neurological outcome of term 
neonates with perinatal asphyxia following IV Magnesium sulphate. 
(26, 27) 
 The required serum therapeutic levels of magnesium (1.5 – 2.5 
mmols/L) can be achieved with a dose of 250mg/kg given once daily 
as slow IV bolus infusion [29]. Both IM &IV routes have been 
recommended in adults in the management of pre eclampsia & 
eclampsia [30]. Intramuscular Magnesium sulphate is used in 
neonates for treatment of hypomagnesaemia & tried in the 
management postnatal apnea [31, 32]. Anticonvulsant effect start 
almost immediately following IV Magnesium sulphate and is 
maintained for one hour. Peak action is achieved by one hour and lasts 
for 3-4 hours following IM Magnesium sulfate [33]. Hypotension & 
respiratory depression is known to occur with intravenous route and 
hence close monitoring is required [33]. 
Intramuscular route of magnesium sulphate has not been tried in 
neonates with perinatal asphyxia so far. We were able to demonstrate 
in a pilot study that neuroprotective levels of serum magnesium as 
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recommended by Levene et al can be achieved with intramuscular 
injection of magnesium sulphate in term babies with perinatal 
asphyxia and the levels could be sustained for 72 hours (unpublished 
data). 
With this evidence a prospective double blind randomised 
placebo controlled trial was planned to determine whether postnatal 
intramuscular Magnesium sulphate treatment can improve the short 
term outcome in neonates with moderate to severe perinatal asphyxial 
encephalopathy. 
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REVIEW OF LITERATURE 
Perinatal asphyxia is an insult to the fetus or neonate due to lack 
of oxygen and/ or lack of perfusion to various organs. The common 
factor is deprivation of oxygen to the Central Nervous System. There 
is a lack of unanimity in the definition of perinatal asphyxia [35]. The 
World Health Organization (WHO) has defined birth asphyxia as 
“failure to initiate and sustain breathing at birth”and a score of less 
than seven at one minute of life, based on Apgar score. 
National Neonatal and Perinatal database (NNPD) 2000, has 
defined moderate perinatal asphyxia as slow gasping breathing or an 
Apgar score of 4-6 and severe as no breathing or an Apgar score of 0-
3 at one minute of life [5]. The essential criteria for for diagnosing 
perinatal asphyxia as stated by the American college of Obstetricians 
and Gynecologist and the American Academy of Pediatrics are – 
1. Prolonged metabolic or mixed acidemia (pH <7) on an 
umbilical arterial cord blood sample.  
2. Apgar score of 0 to 3 for longer than 5 minutes. 
3. Neonatal neurological manifestations eg. seizures, coma or 
hypotonia, and 
4. Evidence of multisystemic organ dysfunction eg. 
Cardiovascular , gastrointestinal, hematological,pulmonary or 
renal system in the immediate neonatal period.[34] 
Birth asphyxia can be caused by events that occur during the 
antepartum, intrapartum or postpartum period. Dillenge et al found 
that asphyxia is primarily antepartum in origin in 50% of cases, 
intranatal in 40% and postnatal in 10% of cases [35]. In developed 
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countries with advanced obstetric care, asphyxia is predominantly 
antenatal in origin or due to intranatal events superimposed on already 
existing risk factors [4]. 
 
 
 
 Risk factors for newborn encephalopathy        
 In developing countries studies assessing the timing of insult in 
an asphyxiated infant are not available.  Due to lack of skilled care and 
higher incidence of complication during delivery intrapartum causes 
of asphyxia predominate [36]. 
Ischemia and hypoxia are the two forms of oxygen deprivation 
during asphyxia, of which ischemia is more important. Cerebral blood 
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flow (CBF) is maintained at a constant level over a broad range of 
perfusion pressure.This autoregulation of cerebral blood flow which is 
operative in both preterm and term infants, results from arteriolar 
vasoconstriction during increased perfusion pressure and vasodilation 
during decreased perfusion pressure [6]. 
 
Approximate regulatory 
range is 25 to 50 mmHg mean arterial blood pressure.The size of the 
range vary with gestational age and post natal age [11]. 
During moderate to severe asphyxia cerebral vascular 
autoregulation is impaired and CBF becomes passively related to 
arterial blood pressure (pressure passive cerebral circulation). The fall 
in the arterial blood pressure following asphyxial insult leads to 
decrease in CBF and injury to certain vulnerable brain cells (selective 
neuronal necrosis).This selective vulnerability of neuronal groups is 
also due to regional vascular factors and regional metabolic factors. 
Neuronal injury due to perinatal hypoxia and ischemia is initiated 
during the insults and extends into the recovery period. 
Neuronal injury occurs in two phases. The primary phase occurs 
during the asphyxial insult and if not corrected leads to a cascade of 
biochemical events and necrotic cell death. This is primarily due to 
cellular hypoxia which interrupts oxidative phosphorylation and 
depletes high energy phosphate reserves.There is a switch to anaerobic 
respiration and glycolysis becomes the sole source of ATP (an 
inefficient method of ATP gneneration). This primary energy failure 
leads to neuronal membrane depolarisation (failure of ATP dependent 
Sodium Potassium pump) and loss of membrane ionic homeostasis. 
When ATP level falls below 20% of normal, neuronal injury becomes 
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irreversible. Synaptic and neuronal conductivity ceases. There is 
influx of sodium into neuronal cells which is followed by water influx. 
This leads to cellular edema and necrotic cell death. 
 
Mechanism of  neuronal injury in Hpoxic-Ischemic insult 
 
 
 
Also there is a cellular efflux of potassium which induces 
release of glutamate (excitatory neurotransmitter) into synaptic cleft 
and this coupled with failure of energy dependant reuptake leads to 
increased accumulation of glutamate in neuronal extracellular fluid. 
The regional distribution of glutamate receptors, namely N- methyl  
D-aspartate (NMDA) and alpha amino 3-hydroxy 5-methyl  
4-isoxazole propionic acid (AMPA) types, appears to be one of the 
important determinant of distribution of selective neuronal injury. 
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Glutamate receptors: 
TYPE Function 
Inotropic 
1. NMDA receptors 
2. AMPA receptors 
3. Kainate receptors 
 
Ca++ entry, Na+ entry 
Na+ entry, Ca++ entry( in 
immature neurons 
Na+ entry 
Metabotropic receptors 
         Ibotenate 
Mobilizes Ca++ from endoplasmic 
reticulum 
 
Activation of NMDA receptors by glutamate and increased 
permeabilty to calcium   in AMPA receptors( in immature neurones) 
leads to increase in cytosolic calcium by enhanced Na + influx which 
leads to opening up of voltage dependant calcium channels. Sustained 
membrane depolarisation leads to sustained glutamate release and 
failure of glutamate uptake.This leads to activation of degradative 
enzymes like phospholipases A2, Nitric oxide synthase and proteases 
(Calpain). There is increased generation of free radicals,inhibition of 
oxidative phosphorylation and direct DNA damage leading to cell 
death (excitotoxic injury)[7]. 
During reperfusion and recovery following resuscitation, 
secondary neuronal damage occurs through large number of known 
pathways of excititotoxicity leading to mitochondrial failure. This 
secondary phase of injury occurs slowly (hours to days) and with a 
normal intracellular pH and stable cardio respiratory status [37]. The 
cellular response during this phase of neuronal injury is similar to the 
primary phase leading to a decrease in the high energy phosphate 
reserves (secondary energy failure). 
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Reperfusion also attracts monocytes and subsequent 
inflammation to the site of injury. Additionally reperfusion triggers a 
cascade of pathologic processes that leads to accumulation of 
excitotoxic amino acids, increased cytosolic Ca++, generation of free 
radicals and activation of phospholipases. Increased intracellular 
calcium activates a cascade of proteolytic enzymes (especially 
caspases or cystein proteases) leadindg to nuclear fragmentation [38]. 
Microglial activation after hypoxia-ischemia and reperfusion 
promotes release of reactive oxygen and nitrogen species as well as 
cytokines, especially IL-1 and TNF-alpha, which further adds to the 
neuronal injury [11].  
Thus secondary neuronal injury is a consequence of 
excitotoxicity, inflammation, mitochondrial failure, apoptosis and 
cytotoxic actions of activated microglia rather than the result of 
cellular destruction.The severity of secondary energy failure correlates 
with the severity of seizures and adverse neurological outcome [39]. 
 
The clinical features of Hypoxic Ishchemic Encephalopathy 
(HIE) can range from subtle findings like hyper alert state with mild 
hypertonia to severe manifestations like stupor, coma and profound 
hypotonia and absent deep tendon reflexes. Sarnat HB and Sarnat MS 
had devised a three stage grading system of mild (stage 1), moderate 
(stage 2) and severe (stage 3) based on clinical symtoms and EEG 
evaluation [40] .The severity of clinical encephalopathy correlates 
strongly with neurodevelopmental outcome [41]. 
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 Postnatal management of depressed infants begins in the 
delivery room by following the latest Neonatal Resuscitation 
Programme guidelines [42]. Supportive therapy along with close 
monitoring and treament of complications forms the mainstay of 
management of neonatal HIE.  
Neuroprotective therapies are aimed to ameliorate the secondary 
neuronal injury which progresses for about 72hours after primary 
neuronal injury.  Therapeutic hypothermia (whole body or head 
cooling) with supportive care  significantly improves the neurologic 
outcome in full-term infants with moderate to severe encephalopathy 
[43, 44, 45, 46]. 
The other potential neuroprotective therapies are grouped as 
follows  
 1) Agents that inhibit glutamate release (Excitatory aminoacid 
antagonist)  
- By blocking of presynaptic voltage dependant sodium 
channels,  eg. Phenobarbitone [47]. 
-  By activating presynaptic adenosine (A1) receptors [48]. 
- By blockade of synaptic transmission or blockade of post 
synaptic glutamate receptors, eg. Magnesium. 
2)  Blockade of free radical generation or free radical scavengers 
eg.Allupurinol, desferroxamine, nitric oxide synthase inhibitors 
[49] 
3)  Calcium channel blockers: Inhibition of cytosolic calcium 
accumulation by blocking the entry routes of calcium from the 
extracellular compartment or from intracellular stores. 
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Flunarizine has been shown to reduce the extent of hypoxic-
ischemic damage in experimental animal models [50]. 
4) Aminoacid derivatives: HIE disrupts mitochondrial funcution. 
Acyl CoA molecules accumulate during ischemia and inhibit 
multiple enzymes. This blocks multiple biochemical cycles like 
citric acid and urea cycle, glycolysis, gluconeogenisis and 
catobolism of proteins & fat. Exogenous aminoacid derivative 
like carnitine facilates transport of acyl moieties across 
mitochondrial membranes and thus removes the potentially toxic 
acyl CoA moieties.  L carnitine has been shown to significantly 
reduce the severity of neuronal injury in newborn rats [51] 
5) Erythropoetin has been shown to faciltate recovery of sensory 
motor function following hypoxic ischemic insult in neonatal rats 
[52] 
6)  Opioids have been found to be neuroprotective. Retrospective 
review of neonates who had suffered hypoxic ischemic insult 
showed that those who were treated with opioid drugs had less 
brain injury[53]. 
Among the available glutamate receptor blockers those that act 
on NMDA and AMPA receptors have received maximal attention, eg. 
Dextromethorphan, Ketamine, Dizocilpine and Magnesium. 
Magnesium blocks glutamate receptors within the calcium ion 
channels. Magnesium, NMDA receptor antagonist inhibits glutamate 
mediated excitotoxicity and prevents neuronal influx of Ca++.                    
In experimental animal models after simulated hypoxic insults, 
Magnesium was found to be beneficial in limiting the neuronal 
damage in some studies. 
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 Spandou E et al found that magnesium sulphate administration 
resulted in significant protection against moderate hypoxic ischemic 
brain damage, in seven-day old rats  that underwent unilateral carotid 
artery ligation followed by 1 or 2 hours of hypoxia (8% O2)  [17] .   
 Mami AG et al studied the effect of magnesium sulphate 
administration to newborn piglets subjected to severe hypoxia and 
those with normoxia.The results showed that magnesium sulphate 
administration prior to hypoxia prevents hypoxia induced increase in 
intranuclear calcium and IP3 receptor modification and concluded that 
Magnesium administration prevents hypoxia-induced modification of 
neuronal nuclear membrane function that leads to intranuclear 
Calcium dependent transcription of apoptotic proteins leading to 
hypoxic neuronal programmed cell death[54]. 
Cetinkaya M et al studied the neuroprotective effect of 
magnesium on the brain infarct volume in neonatal hypoxic rat 
model.The percent of infarcted brain volume was significantly 
reduced in pups who received magnesium compared to those who 
received saline thus highlighting the possible beneficial effect of 
magnesium in hypoxic encephalopathy [18, 20]. 
Greenwood K et al and Penrice J et al did not document any 
beneficial effect following Magnesium sulphate administration in 
newborn piglets subjected to hypoxic ischemic insult [19, 20] . 
In human studies, mothers exposed to antenatal Magnesium 
sulphate therapy for eclampsia and for mangement of preterm labour 
showed decreased risk of germinal matrix or intraventricular 
haemorrhage in their Very Low Birth Weight (VLBW) babies. [55] 
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Schendel DE et al studied the relationship between prenatal 
magnesium sulphate exposure and risk of Cerebral palsy (CP) or 
mental retardation (MR) among VLBW neonates. It was a cohort 
study with a follow up upto one year and a subset of cohort followed 
for five years. The study population was VLBW infants delivered over 
a period of two years and those among them who survived till infancy. 
The outcomes measured were  
1) Infant mortality among the VLBW infants as determined by the 
vital statistics record. 
2) Development of CP or MR in those who survived for three to 
five years from the Developmental Disability Surveillance 
programme. 
Among the VLBW infants followed there was no association 
between prenatal magnesium sulphate exposure and infant mortality, 
the adjusted Odds Ratio (OR) being 1.02, 95% Confidence Interval 
(CI) 0.83 to 1.25. 
Among the survivors who were followed till 3 to 5 yrs there 
was a lower prevalance of CP/MR in those exposed to prenatal 
magnesium sulphate (0.9% in those exposed to magnesium and 7.7 % 
in those not exposed.Crude OR- 0.11, 95% [CI  0.02 to 0.81] for CP 
)[21]. 
     Nelson K et al analysed singleton infants who weighed less than 
1500gms at birth and had developed moderate to severe cerebal palsy 
at three years of age. He compared them with randomly selected 
control survivors (with out cerebral palsy) with respect to whether 
their mothers had received antenatal magnesium sulphate for any 
reason. Among mothers whose infants had developed cerebral 
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Palsy 7.1% were exposed to antenatal magnesium as against 36 % of 
mothers whose infants did not develop cerebral palsy (OR: 0.14, [95% 
CI: 0.05-0.51]) suggesting a protective effect of magnesium against 
CP in VLBW babies [22]. 
Rouse DJ et al in their randomised placebo  controlled double 
blind multicentric trial of maternal magnesium sulphate  therapy for 
the prevention of cerebral palsy found moderate or severe cerebral 
palsy occurred significantly less frequently in mothers who had 
received i.v magnesium sulphate than in those who did not   (1.9% vs. 
3.5%; relative risk, 0.55[ 95% CI, 0.32 to 0.95]) . The risk of death did 
not differ significantly between both the groups. This study also 
suggests that fetal exposure to magnesium sulfate before anticipated 
early preterm delivery reduced the rate of cerebral palsy among 
survivors [56].  
Grether et al evaluated the association between intrauterine 
exposure to magnesium sulphate and neonatal death. They found that 
magnesium sulphate tocolysis was not associated with increased 
neonatal mortality in premature infants. Thus selective mortality of 
vulnerable infants was not the cause for any association of magnesium 
with reduced long term neurologic morbidity [23]. 
Ichiba et al in their multicentric randomized controlled trial of 
iv injection magnesium sulphate in term neonates with moderate to 
severe asphyxial encepahlopathy found that there was a significant 
short term neurologic benefit among the neonates who received iv 
magnesium (250 mg/kg) once a day for 3days.  Survival with normal 
results of cranial computed tomography, electroencephalography and 
establishment of oral feeding by 14 days of age, was significantly 
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more frequent in the treated group than in the control group (12/17 vs 
5/16, P = 0.04)[26].  
The same group of authors tested the neuro protective effect and 
the safety of injection magnesium sulphate given as i.v infusion along 
with dopamine infusion to neonates with severe perinatal asphyxial 
encepahalopathy. They found that postnatal infusion of magnesium 
sulphate with dopamine caused no change in physiological variables. 
Deaths and neurological sequelae  at 18 months were less frequent 
than in reported cases( historical control) with the same grade of 
severity  of HIE, and suggested that this treatment may improve 
neurodevelopmental outcome in infants with severe birth 
asphyxia[27]. 
In a recent double blind randomized controlled trial, Bhat MA 
et al showed that postnatal magnesium sulphate infusion within six 
hours of life in term neonates with severe perinatal asphyxia is 
effective in improving the short term neurologic outcomes. Neurologic 
abnormalities at discharge were significantly less in the treatment 
group (4 of 18) when compared to placebo group (10 of 18). [OR: 
0.22, 95% CI: 0.05-0.9]. There was no significant difference in the in 
the number of infants initiated on direct breast feeds  by seven days of 
hospitalisation,  results of computerized tomography of  brain on day 
14 of life and  the EEG changes between the treatment and placebo 
group. However a composite measure of no neurological abnormality, 
normal neuroimaging, normal EEG finding and oral feeding by 
sucking at discharge was present in 77% of neonates (14 of 18) in the 
treatment group and 37 % (7 of 18) in the placebo group. (OR: 5.5, 
[95% CI: 1.2-23.6] P<.02)[28]. 
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Perinatal asphyxia and neonatal encepalopathy is more common 
in developing countries. Suboptimal intrapartum monitoring further 
increases the risk of asphyxial encephalopathy in level-1 and level-2 
settings (Domiciliary delivery & delivery at Primary health centers) 
[36]. Availabilty of skilled personnel and optimal monitoring is 
mandatory for early initiation of i.v magnesium sulphate infusion in 
neonates with moderate to severe perinatal asphyxia. In this context 
Intramuscular injection (IM) of magnesium sulphate would be an 
effective alternate route. 
Injection magnesium sulphate is used in neonates to treat 
neonatal hypomagnesemia and refractory neonatal hypocalcemia[57]. 
It can be administered both by Intramuscular (IM) and intravenous 
route (IV). In adults the therapeutic levels of serum magmesium (1.8-
1.3 mmol/l) are achieved by both i.v and IM route. [30]. Following IV 
magnesium sulphate the onset of action is almost immediate and 
maintained for 30 minutes. The onset of anticonvulsant action takes 
about one hour following intramuscular route and is maintained for 
three to four hours [58]. 
The required neuroprotective levels as recommended by Levene 
et al is 1.5- 2.5 mmol/L[29]. There are very  few studies available in 
neonates to demonstrate that IM magnesium achieves therapeutic 
levels of serum magnesium[ 31,32].  
A pilot study was conducted in our neonatal intensive care unit 
which showed that neuroprotective levels of serum magnesium were 
achieved and maintained for 72 hours following three doses of 250 
mg/kg/day of IM magsulf in neonates with asphyxial encephalopathy. 
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Adverse effects like hypotension, shock & respiratory depression were 
not of significant concern during therapy [Unpublished data]. 
Term babies (≥37wks), born with severe perinatal asphyxia and 
less than six hrs of age at the time of admission were given three  
doses of 0.5 mL/kg per dose of 50% Inj. Magsulf (250mg/kg/dose)  
deep IM, in 2 equal halves, in each thigh. Serum magnesium levels 
were estimated at recruitment (0 hours), 2, 24, 26, 48, and 50 and at 
72hours after the first injection. An average rise of 1.24mmol/L in the 
mean serum magnesium levels from the base line value follwing each 
IM injection of magnesium sulphate   was documented (P< .001) and 
this was sustained for 24 hours after the third injection.  
This paved the way to conduct a prospective randomized 
placebo controlled trial to determine if IM magnesium sulphate 
administered within six hours after birth improves the short term 
outcome (death or survival with neurological impairment) in neonates 
with severe perinatal asphyxia. 
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Hypothesis :  
 Magnesium a naturally occurring NMDA receptor blocker acts 
as a neuroprotective agent by reducing secondary neuronal injury in 
moderate to severe asphyxia encephalopathy. 
 
Justification :  
 Intravenous magnesium sulphate has been shown to be 
neuroprotective in neonatal  asphyxia injury by few authors. It 
probably reduces secondary neuronal injury through its NMDA 
receptor blockade effect. Intramuscular Magnesium may be an 
effective alternative for resource poor settings where the incidence of 
perinatal  asphyxia is high and facility for intravenous infusion may 
not be always available. 
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AIMS AND OBJECTIVES 
Aim of the Study 
To determine whether intramuscular magnesium sulphate given within 
six hours  after birth improves the short-term outcome in neonates 
with severe Perinatal Asphyxia.  
Objectives of the study: 
Primary Objective: Death or survival with neurological impairment 
Secondary Objectives: 
 1) Serum. Magnesium levels  
2) Progression of severity of encephalopathy 
3) Need for assisted ventilation   
4) Incidence of seizures  
5) Hypotension requiring inotropic support 
6) Time taken for achieving full oral feeds  
7) Abnormal findings in neurosonogram done before discharge 
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MATERIALS AND METHODS 
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MATERIALS & METHODS 
Setting: Tertiary care Maternity hospital with around 15,000 
deliveries per year (Inborn unit) and Tertiary care 500 bedded 
Paediatric hospital (Out born unit) in Chennai, Tamilnadu. 
Subjects: Population consisting of all neonates ≥36 weeks, born either 
vaginally or through caesarean section. 
Sample size:   
Based on previous Indian studies with an alpha error of 5% and 
power of 80%, 116 neonates (58 in each group) with moderate to 
severe asphyxia were studied to allow a detection of 25% reduction in 
the primary outcome. 
Inclusion Criteria: 
Babies (≥36wks), less than six hrs of age at the time of 
admission and born with severe perinatal asphyxia were eligible for 
the study. 
Definition of perinatal asphyxia - babies with any 2 of 
following 3 criteria 
i) H/O fetal distress (late deceleration, fetal bradycardia, 
meconium stained amniotic fluid). 
ii) Need for assisted ventilation initiated at birth & continued 
for more than two minutes after delivery.  
iii) Apgar score of 0 to 3 at 1minute of age. 
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Neonates were candidates for the study when moderate to 
severe encephalopathy or seizures were present within six hours of 
life. 
Moderate to severe HIE was diagnosed in these neonates when 
more than one sign was present in 3 of the following 6 categories. 
Criteria for defining moderate to severe encephalopathy 
 
 
 
Category      Hypoxic Ischemic Encephalopathy 
 Moderate Severe 
Level of 
consciousness 
Lethargic Stupor/ coma 
Spontaneous activity Decreased No activity 
Posture Distal flexion or 
complete 
extension 
Decerebrate state 
Tone Hypotonia-
focal/general 
Flaccid 
Primitive reflexes   
                     Suck Weak Absent 
                      Moro Incomplete Absent 
Autonomic system.   
                  Pupils  Constricted Deviated , dilated 
or nonreactive to 
light 
                  Heart rate Bradycardia Variable 
              respiration Periodic breathing Apnea 
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Exclusion criteria: 
      No features of HIE by six hours of age. 
      Major congenital anomalies requiring surgery,  
      Suspected inborn error of metabolism,   
      Chromosomal anomalies / syndromes associated with cerebral 
dysgenesis 
Design: Doubled blind randomized controlled trial. 
Study period:  May 2012 to February 2013 
A written consent was obtained from the parents / care givers of 
the neonate, for willingness for enrolment in the study, after 
explaining to them about the study. 
Randomisation: Randomisation was done through computer 
generated random numbers placed in opaque envelops. Eligible 
neonates were randomised into  Group-1 (study group) and Group-2 
(placebo group).  The computer generated code for the intervention 
drug was available with the Guide and Co-Guide only. 
Intervention: 
Group I received 3 doses (0.5 ml/kg per dose) of 50% Inj. 
Magnesium sulphate as IM, 24 hours apart given as 2 equal halves 
deep IM on each thigh (250mg/kg/dose). Group II received 3 doses 
of 0.5ml/kg per dose of Placebo (normal saline) as IM, 24 hrs apart 
given as 2 equal halves deep IM on each thigh. 
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Infants in both the groups were nursed on servo-controlled, 
open-care beds, with skin temperature maintained at 36.5°C. On day 1 
of life, 10% dextrose solution was administered as the maintenance 
intravenous fluid; electrolytes were added from day 3 of life. Full 
maintenance fluids were administered initially. If syndrome of 
inappropriate antidiuretic hormone secretion was proved, fluids were 
restricted. Depending on the condition of the infant, respiratory 
support in the form of oxygen therapy or mechanical ventilation and 
pressor support in the form of dopamine or dobutamine infusion was 
provided as per standard unit protocol. During the initial 72 hours of 
life, heart rate, respiratory rate, and oxygen saturation were monitored 
continuously. Blood pressure was  monitored every 15 minutes during 
the first hour and hourly for subsequent 6 hours through non invasive 
blood pressure monitoring. After 6 hours blood pressure was 
monitored every 4 hours. 
 Assessment of parameters: 
The following clinical assessments were made after enrolment.  
- Assessments of the neurological status at admission, during the 
stay & at discharge,  
- Progression of HIE,  
- The type of respiratory support needed, 
- Requirement of inotropic support      
- Presence of seizures,  
- Time taken for establishment of full oral feeds (paladai / breast 
feeding) 
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- Neurological examination was performed in the Department of 
Child Development Clinic in our Hospital at the end of two 
weeks or at discharge whichever was earlier. 
The principle investigator, day to day care givers and the person 
carrying out the neurologic examination were blinded regarding the 
drug given to the neonate. 
Normal Saline and inj. Magnesium sulphate were packed in 
similar shaped transparent glass ampules containing 2ml of the 
respective drugs. They were made to look similar by masking after 
removing the lables. This made it difficult to differentiate one from 
the other.  
A Certifcate of Analysis was obtained from approved laboratory 
for both. Normal saline and Inj. Magnesium sulphate, regarding pH, 
particulate matter, composition as per label claim and test for sterility.  
Both the drugs fulfilled the prescribed standards of USP, with respect 
to the tests carried out [annexure-2 ].   
Outcome: 
The following outcomes were analysed 
Primary outcome: Death or survival with neurologic impairment. 
Secondary Outcomes: 
 - Sr. Magnesium levels in IM & placebo Group. Serum 
magnesium was analysed by Calmagite method[59]. 
 - Hypoxic ischemic encephalopathy, its severity & its 
progression  
 - Need for assisted ventilation 
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 - Seizures requiring anticonvulsants 
 - Hypotension requiring inotropic support. 
 - Time taken for attaining full oral feeds (paladai / direct breast 
feeds)   
 - Abnormalities in imaging studies 
     Ultra sound cranium findings once before discharge or at 
follow up.   
  Abnormal brain CT findings whenever necessary. 
 
STATISTICAL ANALYSIS 
All analysis was performed according to intention to treat 
principle. Standard statistical tests were employed. Normality of the 
data was analysed using Kolmogorov smirnov test. Categorical 
variables were analysed with chi square test and continuous variables 
were analysed using student’s independent t test. Association 
between clinical variables and groups were assessed using chi square 
test. For significant variables, univariate Odds Ratio with 95% 
Confidence interval were given. P value of <0.05 was taken as 
significant. All statistical tests were two tailed tests. 
The study was approved by the institutional Ethical committee, 
No. 08112011. 
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Injection magnesium sulphate 50% (2ml) 
            
 
 
 
Inj. Normal Saline & Inj Magnesium sulphate before masking 
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Inj. Normal Saline & Inj Magnesium sulphate after masking 
          
 
 
Inj. Normal Saline & Inj Magnesium sulphate masked & packed 
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RESULTS AND ANALYSIS 
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RESULTS 
A total of  1615 neonates  admitted to both outborn and 
inborn unit of our hospital over a period of ten months were 
screened for perinatal asphyxia. Three hundred and ninety 
neonates were diagnosed to have perinatal asphyxia. One 
hundred and fifty two babies had moderate to severe asphyxia 
and of these 32 were excluded ( 23 did not develop features 
of encephalopathy within six hours of age,  seven had major 
congenital malformation or suspicion of inborn error of 
metabolism and parents refused consent for enrollment for 
two neonates ).  
One hundred and twenty neonates who fulfilled the 
inclusion criteria were enrolled in the study. Sixty neonates 
were assigned randomly to saline (placebo group) and 60 to 
the magnesium group (treatment group). After randomization 
two parents  chose to withdraw from the study even before 
commencing treatment.  Fifty eight neonates  in each group 
continued treatment and were analysed. The baseline 
maternal and neonatal characteristics  are shown in Table – 1 
& 2. 
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Randomization  Flow  Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig : 1 
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Table.- 1: Baseline maternal Characteristics 
 
 
Maternal  Characteristics 
Group (drug)  
 
Chi 
square 
test(χ2) 
 
Saline,  
n=58 
Magnesium, 
n=58 
Place of  
Delivery – no. 
(%) 
Inborn 17  (29.3) 18 (31) χ2=0 .04 
P   =0.84 Out born 41  (70.7) 40 (69) 
Age of mother in 
years – no. (%) 
< 19 3  (5.2) 1 (1.7) χ2=4.88 
P   =0.18 20-24 33  (56.9) 44 (75.9) 
25-29 17  (29.3) 10 (17.2) 
30-34 5  (8.6) 3 (5.1) 
Parity – no. (%) One 39  (67.2) 42 (72.4) χ2=0.36 
P  = 0.56 Two 19  (32.8 16 (27.6) 
Mode of 
Delivery – no. 
(%) 
Labour 
natural 
40  (69) 40 (69.0) χ2=4.06 
P  = 0.39 
LSCS 
(emerg.) 
10  (17.2) 7 (12.0) 
Assist. 
Breech 
 2 (10.3) 
Instrumental 
delivery 
8  (13.8) 9 (15.5) 
Meconium Stained Liquor- no. 
(%) 
18  (31) 28(48.3) χ2=3.6 
P  = 0.06 
Complications of pregnancy-
no.(%) 
( PIH, GDM) 
7  (8.6) 5 (6.9) χ2=1.53 
P  = 0.67 
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Table -2 : Baseline Neonatal Characteristics 
        
 
Characteristics 
Groups ( Drug )  
Chi square 
test(χ2) Saline 
   n=58 
Magnesium 
n=58 
Sex – no. (%) Male 34 (58.6) 37 (63.8) χ2=o,32 
P  =  0.56  Female 24 (41.4) 21 (36.2 
Gestational age in 
weeks 
– no. (%) 
36-36 6/7   6 (10.3)   3 (5.2) χ2=5.3 
P  =  0.25 37- 39 6/7 38 (65.6) 32 (55.2) 
≥40 14 (24.1) 23 (39.7) 
Age at 1st Inject. – 
no. (%) 
< 3hours 22 (45.1) 15 (25.9) χ2=7.1 
P  =  0.21 
3- 6hhours 33 (56.9) 43 (74.1) 
Mean birth weight in Gms ( SD)* 2797.3(445.9) 2878 (386.49) t=1.04 
P=0.29 
Resuscitation 
– no. (%) 
BMV only 39 (67.2)   40 (69) χ2=1.83 
P  =  0.4 
BMV & BTV 17 (29.3) 13 (22.4) 
± chest comp   2 (3.4)    5 (8.6) 
Duration of 
resuscitation 
            (min)      
2 - 5 39 (67.2) 38 (65.5) χ2=1.83 
P  =  0.4 
6 - 10 17 (29.3) 17 (29.3) 
  >10   2 (3.4)   3 (5.2) 
Apgar score 
– no. (%) 
1minute < 3 53 ( 91.3) 51( 87.9) χ2=0.21 
P  =  0.89 
5minute <6 50 ( 86.2) 48(82.7) 
Onset of seizures within 24 hrs 
                                        – no. (%) 
43 (74.1) 41 (70.7) P=0.67 
HIE stage 
– no. (%) 
Stage 2 47 (81) 46 (79.3) χ2=0.05 
P  =  0.81 
Stage 3 11 (19) 12 (20.7) 
Shock at admission– no. (%) 31(53.4) 37 (63.7) χ2=0.05 
P  =  0.81 
Mean arterial  
pressure ( SD)* 
before Inject. 41.8 (6.16) 41.3(7.2) t=0.14 
p=0.88 
Resp. support at 
admission 
– no. (%) 
Nil 10 (17.2)   8 (13.8) χ2=026 
P  =  0.87 
O2 by CPAP/hood 26 (44.8) 27 (46.7) 
Mech. ventilation 22 (37.9) 23 (39.7) 
 
*SD- Standard deviation, t- student t test 
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Baseline maternal features like place of delivery, maternal age, 
parity, mode of delivery and complications during delivery were 
comparable  between the two groups (Table-1).  
Baseline neonatal characteristics like sex , gestational age, age at the 
time of first injection, mean birth weight, need for resuscitation  and 
the methods used, duration of resuscitation, one and five minute 
Apgar score, onset of seizures, severity of HIE, Mean arterial blood 
pressure, presence of shock and need for respiratory support were 
comparable between the two groups   (Table – 2). 
  
  
Baseline maternal characteristics:
Table-3: Place of delivery of neonates in saline and magnesium group
 
Place of 
Delivery 
Saline
Out born 
        – no. (%) 
41 (70.7%)
Inborn 
        – no. (%) 
17 (29.3%)
 
There were 17(29.3%) and 41 ( 70.7%) inborn and out born 
neonates respectively in the saline group. There were 18( 31%) inborn 
and 40 (69%) out born 
no significant difference in the number of babies included from inborn 
and out born deliveries between
(Table- 3  , Fig. – 2). 
 
Fig.   2 : Place of delivery of neonates in saline 
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Table- 4: Age of mothers of neonates included in the study
 
Age of mothers 
 
– no. (%) Saline, n=58
< 19yrs   3 (5.2%)
20  - 29 yrs 50 (86%))
30 – 34 yrs   5(8.6%)
 
There were totally four mothers who were less than 19 years of 
age.  Three in saline and one in magnesium group. Eight mothers were 
in the age group 30 to 34 years, five in saline and three in magnesium 
group respectively. Majo
to 29 years in both the groups (Table
    
Fig .- 3. Age of mothers of neonates included in the study
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Table-5: 
 
Mode of delivery 
Labour natural 
LSCS 
Breech 
Instrumental 
Delivery 
– no. (%) 
Most of the neonates included in the study were born normally 
(40  in both the groups). Ten neonates in saline and six neonates in 
magnesium group were delivered by emergency LSCS. Instrumental 
delivery accounted for eight and nine cases in saline and magnesium 
groups respectively.There was nos ignificant difference 
mode of delivery between the two groups (Table
Fig. -4. Mode of delivery in both the groups
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Table – 6: 
Parity of 
mothers 
Saline, n=58
Para-1   3 9(67.2%)
Para-2 19 (32.8%))
– no. (%) 
Most of the mothers were primiparus , 39 (67.2%) and 42 
(72.4%) respectively in saline and magnesium group
History of meconium stained liquor was present in 18 (31%) of 
neonates in saline group and in 28 (48.3%) in magnesium group. This 
difference was statistically not significant. 
There was no difference in the presence of complications  of  
pregnancy like  pregnancy induced hypertension and diabetes mellitus 
complicating pregnancy (7 in saline and 5 in magnesium group).
 
Fig-5: Parity of Mothers in both the groups
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Baseline Neonatal Characteristics
 
There were totally 71 male and 45 female neonates enroled in 
the study. Thirty four male and 24 female neonates were included in 
the saline group. Thirty seven male and 21 female neonates were 
included in the magnesium group. There was no statistical 
significance in this regard 
 
                                                       
Fig. 6. Distribution of gender in both the groups
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Table- 7 : Gestational age of neonates included in the study
Gestational age 
in weeks 
Saline, n=58
36 - 36 6/7   6 (10.3%)
37 – 39 6/7 38 (65.6%))
≥ 40   14(24.1%)
– no. (%) 
Thirty eight (65.6%) and 32(55%) neonates were in the 37 
6/7 weeks gestational age group in the saline and magnesium group 
respectively. Fourteen (24.1%) and 23 (39.7%) neonates were more 
than 40 weeks of gestation in the saline and magnesium group. T
was no statistically significant difference regarding gestational age 
between the two groups. 
Fig.- 7: Gestational age of neonates included in the study
0
20
40
60
80
36 - 36 6/7 
wks
10.3
5.2
Group Chi square 
test(χ
 
 Magnesium,n=58 
 3 (5.2%) χ2=5.3 
P  =  0.25
 32 (55.2%) 
 23(39.7%) 
(Table-  7, Fig -7). 
37 - 39 6/7 
wks
≥ 40 wks
65.6
24.1
55.6
39.7
Saline
Magnesium
 
44 
 
2) 
 
– 39 
here 
 
 
  
Table
Age at 1st 
injection In 
hours Saline, n=58
< 3    25(45.1%)
 3 -6  33 (56.9%))
– no. (%) 
About 60- 70% of neonates in both the groups received their 1st 
injection between 3 –
saline group and  15 (25.9%) in the magnesium group received their 1 
st injection at less than 3 hours of age. This differe
statistically significant. 
Fig.
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There was no statistically significant difference in the mean 
birth weight of neonates between the two groups (2797 ±445.9 gms.  
in saline group and 2878.6 ±386.5gms in magnesium group) Table -2.   
All babies had received resuscitation soon after birth. Bag and 
mask ventilation was the most commonly used method of positive 
pressure ventilation, 39 (67.2%) in saline and 40 (69%)  in magnesium 
group. Seven babies (2 in saline and 5 in magnesium group) had 
received ventilation, Chest compression and ± medications.  
About 65% of neonates were resuscitated for 2 - 5 minutes. 
Seventeen (29%)  neonates  in both the groups were resuscitated for 6 
- 10 minutes.  Only five neonates had required resuscitation for more 
than 10 minutes ( 2 in saline and 3 in magnesium group). The need for 
resuscitation and the method used  and the duration of resuscitation 
were comparable in both the groups (Table – 2). 
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Table.-  9   : HIE stage at the time of admission 
HIE Stage Group Chi square 
test(χ2) 
 Saline, n=58 Magnesium, 
n=58 
Stage -2   47(81.0%) 46(79.3%) χ2=0.05 
P  =  0.81 
 Stage -3 11 (19%)) 12(20.7%) 
– no. (%) 
Regarding Hypoxic ischemic encephalopathy in the two groups 
recruited, there was no significant difference in the severity of HIE.  
(47 had HIE stage 2 and 11 had HIE stage 3 in the saline group. Forty 
six and12 neonates had HIE stage 2 & 3 respectively in the 
magnesium group. (Table- 9,  Fig.- 9). 
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Primary Outcome: 
Table – 10 : Primary outcome 
 
 
Outcome 
Groups Chi square 
test Saline 
n= 58 
magnesium 
n = 58 
 
Death  – no. (%) 
22 (37.9) 24 (41.4) χ2=0.14 
p=0.70 
Death / survival with abnormal 
neurological examination – no. 
(%) 
32 (62.1) 28 (48.3) χ2=0.14 
p=0.70 
Normal neurological 
examination@ 
Discharge/D14* – no. (%) 
26 (72.2) 30 (88.2) χ2=2.80  
p=0.09* 
 
SD- standard deviation,  *? Trend towards significance. 
 
1) There were 22 (37.9%) deaths in saline group and 24 (41.4%) 
deaths in magnesium group. This slight increase in the deaths in 
magnesium group had no statistical significance.  
2) Among the survivors, those with normal neurological 
examination were more in the magnesium group 30 of 34 
(88.2%) than in the saline group 26 of 36 (72.2%). This 
difference showed a trend towards significance (χ2=2.80,  
p=0.09). 
3)  Combined outcome of death or survival with neurological 
impairment was more in the saline group, 32 of 58 (62.1%) vs 
28 of 58 (48.3%). This difference was statistically not 
significant (Table – 10, Fig- 10). 
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Fig 10.  primary outcome 
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Secondary outcomes: 
 
Table – 11 : Mean age when oral feeding  by direct breast feeds (DBF) 
was initiated and mean age at discharge.           
 
 
           Seconary Outcomes 
Groups Student 
independent 
T-test Saline 
  n =58 
magnesium 
n = 58 
Mean age of initiation of DBF 
                                         (SD) 
8.24 
(6.20) 6.28 (4.42) 
t=1.97 
p=0.05* 
Mean age at discharge ( SD) 10.59 
(6.28) 8.61 (5.29) 
t=1.48 p=0.14 
 
Normal Cranial Ultrasound 
examination in survivors-no,(%).                                           
saline, n=36. Magnesium,n=34. 
16 (44.4) 24(70.5) 
χ2=4.01 
p=0.05* 
SD- standard deviation, *trend towards significance 
 
1) The mean age at which oral feeding by direct breast feeds, were 
initiated   was 8.4 days in saline group and 6.2 days in the 
magnesium group (t=1.97, p=.05).  Similarly the mean age at 
discharge was less in the magnesium group 8.61 vs 10.59 days 
(p=0.14).   This early initiation of feeding and earlier discharge 
of neonates in the magnesium group showed a trend towards 
statistical significance when compared to saline group ( Table 
11 , Fig.- 15). 
2) Ultrasound examination of the cranium among the survivors 
before discharge, was normal in 16 out of 36 neonates in the 
saline group and 24 out of 34 in the magnesium group. This 
difference showed a trend towards statistical significance 
(χ2=4.01, p=0.05). 
 
  
 
 
Fig. 11   : Mean age of initiation of DBF & age at discharge
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3) An other important secondary outcome in this study was to 
confirm whether neuroprotective levels of serum magnesium 
were achieved following IM magnesium sulphate. The results of 
the analysis clearly showed that the serum magnesium levels 
were comparable before the 1st injection between the two 
groups. The levels in the magnesium group were significantly 
higher  ( P = 0.001) at 2 , 23 , 26, 47, 50 and at 71 hours after 
the first injection. The serum magnesium level increased from a 
mean level of 0.98 to 2.35 mmol/L  two hours after the first 
injection, 1.78 to 2.62mmol/L   two hours after the second 
injection , 1.98 to 2.61mmol/L  two hours after the 3rd injection. 
At 71 hours the level was 2.11 mmol/L.  Therefore the mean 
serum magnesium levels remained more than 1.2 mmol/L 
throughout the 72 hours after the 1st injection of magnesium.  
The maximum serum levels were achieved two hours after the 
2nd injection (2.62 ±0.59). (Table. 12  , Fig. 12). 
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Table  12  :  Mean serum magnesium levels before and after 
injection(mmol/L) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time of measurement of 
serum magnesium levels 
Group Student 
independent 
T-test saline 
 
 
magnesium 
 
 
 
Day 1 
n=mean 
(SD) 
Before Inj. 
.94 (.21) .98  (.22) t=1.03 p=0.30 
 
2hrs after Inj. .97 (.20) 2.35 (.55) 
t=16.58 
p=0.001 
 
Day 2 
n= mean 
(SD) 
Before Inj. (23 
hrs) .94 (.19) 1.78 (.50) 
t=11.58 
p=0.001 
After Inj.    
(26hrs) .88 (.20) 2.62 (.59) 
t=17.82 
p=0.001 
 
Day 3 
n= mean 
(SD) 
Before Inj. 
(47hrs) .97 (.21) 1.98 (.53) 
t=12.50 
p=0.001 
After Inj.    
(50hrs)  .95 (.20) 2.61 (.57) 
t=16.79 
p=0.001 
 71 hrs  
.95 (.20) 2.11 (.52) t=13.68 p=0.001 
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Fig. 12 : Mean serum magnesium levels before and after 
injection(mmol/L) 
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Table -13  : Hospital course 
 
 
Progress of symptoms 
Groups  
Chi 
square 
test 
Saline 
n= 58 
Magnesium 
n= 58 
 
Response of 
seizures to AED. -
no. (%) 
Nil 13 (22.4) 19 (32.8) χ2=1.58 
P  =  0.45 Controlled 32 (55.2) 27 (46.6) 
refractory 13 (22.4) 12 (20.7) 
Need for 
mechanical 
ventilation Day 1 – 
4.  
– no. (%) 
Yes 12 (33.3)   9 (25.7) χ2=0.49 
P  =  0.48 
No 24 (66.7) 26 (75.3) 
Mech. Ventilation   > 4 days 
                                   – no. (%) 
11 (30.3) 12 (21.9) χ2=0.11 
P  =  0.73 
Shock – no. 
(%)~ 
Inotrope 
responsive 
25 (44.8)   34 (58.6) χ2=4.98 
P  =  0.08 
Refractory 
shock 
   5 (8.6)   3 (5.1) 
CCF/PPHN                 – no. (%) 
   4 (6.8)   7(12) χ2=0.04 p=0.82 
Complication of DIVC 
                                   – no. (%)    3 (5.1)   4 (6.8) 
2=1.93 
p=0.37 
Gastro Intestinal bleed    
                                   – no. (%)                                15 (25) 13 (22) 
χ2=3.63 
p=0.30 
Acute kidney injury – no. (%) 
   9 (15) 13 (22) χ2=4.00 p=0.13 
      
*SD- Standard deviation, t- student t test 
   
  ~ Tachycardia, prolonged CRT, poor peripheral pulses ± hypotension 
    AED- anti epileptic drugs. 
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Hospital course of neonates enrolled: 
Seizure was a predominant symptom among neonates with 
moderate to severe HIE. Forty three (74%) neonates in the saline 
group and 41(70.7%)  in magnesium group had seizures within 24 
hours. Thirteen (22.4%) and 19(32.8%)  in saline and magnesium 
group  respectively did not have seizures after admission. In 32 (56%) 
neonates in saline group and 27 (46.6%) in magnesium group  seizures 
were controlled with  a maximum of two anticonvulsants. Thirteen 
(22.4%) neonates in saline and 12(20.7%) in magnesium group had 
refractory seizures (required more than  two anticonvulsants for 
control). There was no statistically significant difference between the 
two groups regarding presence of seizures, severity and ease of control 
(Table-13).  
Respiratory support at admission in the form of mechanical 
ventilation (MV) was required for 22(37.9%) in saline group and 
23(39.7%) in magnesium group. Twelve (20.6%) in saline and 9 
(15.5%) in magnesium group required ventilation from day 2 to day 4. 
Mechanical ventilation for more than four days was required for 24 
(41.3%) neonates in saline and for 26 (44.8%) in magnesium group. 
The need for mechanical ventilation was not significantly different 
between the two groups (Table – 13).  
Shock as indicated by tachycardia, prolonged CRT, weak 
peripheral pulses, with or without hypotension was present in 
31(53.4%) of neonates in saline group and in 37( 63.7%) in 
magnesium group. In 25(44.8%) of neonates shock was responsive to 
fluids and/or inotropes in the saline group .Thirty four (58.6%) 
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neonates responded to inotropes in the magnesium group. Inotrope 
resistant shock was present in five (8.6%) neonates in saline group and 
three (5.1%) in magnesium group (Table- 13). There was no 
statistically significant difference in the course of shock in the two 
groups   
Other complications that were encountered were PPHN,  
congestive cardiac failure, disseminated intravascular coagulation, 
gastrointestinal bleed, feed intolerance, and acute kidney injury. These  
were similar in both the groups (Table- 13). 
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DISCUSSION 
Our study showed that the combined outcome of death and 
survival with abnormal neurological examination was less in neonates 
treated with IM magnesium sulphate, though this was statistically not 
significant. Neonates with normal neurological examination at 
discharge were more in those treated with IM magnesium. This 
showed a trend towards statistical significance. Similarly the age at 
initiation of direct breast feeds and age at discharge was less in the 
magnesium treated group when compared to placebo and this finding 
too showed a trend towards significance. 
The improvement does not seem to be very obvious, as 
probably magnesium predominantly acts through its NMDA receptor 
antagonistic property only, and reducing calcium influx by inhibiting 
glutamate mediated excitotoxicity. There are several other 
mechanisms of neuronal injury during reperfusion after the asphyxial 
insult like inflammatory injury due to inflammatory cells (monocytes) 
attracted to the site of injury, decrease in phosphocreatine /inorganic 
phosphate ratios leading to secondary energy failure, accumulation of 
excitotoxic aminoacids, generation of free radicals and activation of 
proteolytic enzymes like caspases and cystein proteases leading to 
neuronal apoptosis [11]. Thus a therapy that acts at multiple steps of 
pathogenesis of neuronal injury  like “Therapeutic cooling” may show 
a better outcome.  
In our study we did not use objective methods of assessing 
improvement like changes in MRI images and changes in EEG 
findings.  
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Sonographic examination had shown higher number of normal 
results in the magnesium treated group (trend towards significance). 
However sonography though useful as an initial bed side 
neuroimaging technique, 50% of results in neonates with HIE are 
normal [60]. Also the results depend on the skill of the personnel 
performing the sonographic examination. Magnetic resonance imaging 
and Magnetic resonance spectroscopy are probably the most sensitive 
imaging technique in the examination of neonates with asphyxial 
injury [61, 62]. Thus with MRI more neonates with asphyxial brain 
injury would have been identified and their outcome objectively 
monitored. 
The overall mortality in our study was 40%. This correlates 
with our unit outcome which was used to plan the sample size. Other 
authors have reported much lower mortality rates in neonates with 
asphyxial injury. Bhat MA et al showed an overall mortality of 10% in 
their study [28]. Shankar S et al had shown 27% mortality in their 
control group of neonates with asphyxial injury [45]. Thus this high 
mortality rate could have influenced our study outcome. Basic 
supportive care which is an important part of management of neonates 
with asphyxial injury is needed for other therapeutic measures to be 
effective. 
The inclusion criteria in our study had only clinical markers like 
evidence of fetal distress, Apgar score less than 3 at one minute and 
need for prolonged duration (more than two minutes) of resuscitation.   
Neonates who satisfied the above criteria for asphyxia were included 
in the study only if they developed features of moderate to severe 
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encephalopathy within six hours of age. This prevented neonates with 
mild degrees of encephalopathy and those without encephalopathy 
from being recruited in the study.  The higher rate of overall mortality 
reflects that only those neonates with moderate to severe 
encephalopathy were included in the study. 
Out born neonates were also included in the study as the 
incidence of asphyxial injury is higher in deliveries that are conducted 
at level 1 and level 2 settings and this is where our intervention should 
be implemented. 
The neuroprotective role of magnesium has been demonstrated 
in animal studies by Mayer ML et al, 1984 and by Hoffman DJ, 1994 
[15, 16]. Recent studies by. Spandou E et al, 2007 and   Cetinkaya M 
et al, 2011 have shown possible neuroprotective effect in hypoxic rat 
models [17, 18]. Schendel DE et al and Nelson KB et al had shown 
decreased incidence of cerebral palsy in preterm neonates whose 
mothers had received antenatal magnesium sulphate [21, 22]. Rouse 
DJ et al had shown fetal exposure to magnesium sulphate before 
anticipated preterm delivery reduced the incidence of cerebral palsy 
among the survivors [56]. 
There are only two postnatal human studies that have been 
carried out to determine the role of intravenous magnesium sulphate in 
the management of neonates with moderate to severe asphyxial 
encephalopathy. Ichiba et al had shown that postnatal infusion of Inj. 
Magnesium sulphate improved the short term outcome namely 
survival with normal CT scan result of the brain, normal EEG and 
establishment of oral feeds by 14 days. There was no significant 
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difference in the duration of clinical seizures, need for assisted 
ventilation and mortality [26]. However this was not a placebo 
controlled double blind trial. The same authors in 2006, demonstrated 
long term benefits of IV magnesium sulphate in neonates with 
perinatal asphyxia as shown by improved neurodevelopmental 
outcome at 18 months of age when compared to historical controls 
[27]. 
Bhat et al in their randomized placebo controlled trial with 
postnatal IV magnesium sulphate in neonates with moderate to severe 
asphyxial injury improved survival with normal neurological 
examination in the magnesium treated group. They too did not show 
any difference in the mortality rate between the two groups. A 
composite measure of normal neurological examination, a normal 
result in the CT scan of brain, normal EEG pattern and oral feeding 
through sucking at discharge was significantly better in the 
magnesium treated group [28]. 
Ours is the first study of its kind with postnatal IM magnesium 
sulphate for the treatment of neonates with asphyxial injury. This 
route of administration of magnesium was considered to enable the 
intervention to be implemented in the level 2 and level 3 settings 
where the skill and equipment for IV infusion of magnesium and 
equipments for adequate monitoring may not be available [36]. 
A pilot study carried out in our hospital had demonstrated that 
IM magnesium sulphate given once a day could achieve 
neuroprotective levels of serum magnesium (as recommended by 
Levene et al) which can be sustained for 72 hours [unpublished data]. 
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This finding was confirmed in our present study which had shown that 
mean serum magnesium levels remained above 1.2mmol/L 
(neuroprotective level) with 3 doses of IM magnesium sulphate 24 
hours apart. There were no significant adverse effects like hypotension 
or respiratory depression when compared to placebo group.  
Thus there seems to be a limited but definite role of IM 
magnesium sulphate in the management of neonates with asphyxial 
injury. In combination with other accepted neuroprotective modalities 
of therapy like therapeutic cooling, it may have a synergistic effect.  
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The strengths of our study were: 
1. The robustness of the randomization and blinding of the 
investigators. 
2. Serum magnesium levels were monitored and were found to be 
within the neuroprotective range  
3. A well established Child Developmental Clinic (CDC) performed 
the neurological examination of the neonates at discharge or on 
day 14. 
4. Those neonates who developed moderate to severe signs of 
encephalopathy only were included in the study even though 
clinical markers of asphyxia were used for eligibility criteria.  
The limitations of our study were: 
1. Inclusion criteria had only clinical markers. 
2. Higher overall mortality rates in both the groups could have 
affected the outcome of the study. 
3. Lack of neuroimaging methods like MRI & MRS and EEG 
monitoring prevented us from identifying many more abnormal 
neonates and in documenting neurologic improvement or 
deterioration objectively.  
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CONCLUSION 
• Intramuscular magnesium sulphate probably has a 
neuroprotective role in   neonates with asphyxial injury. 
•  Magnesium does not alter the mortality rate but reduces 
neurological impairment among survivors. 
• Intramuscular magnesium once a day for three days can achieve 
neuroprotective levels of serum magnesium, which can be 
maintained for 72 hours. 
• Adverse side effects like hypotension or respiratory depression 
were not a concern with this route and dose. 
• Neonates who had normal neurological examination at 
discharge or on day 14 may need a long-term 
neurodevelopmental follow up to be definitive about their 
outcome. 
• Though the present study could not convincingly demonstrate 
the neuroprotective role of magnesium , a larger study with a 
longer follow up period, with additional  support of MRI and 
EEG technique may give better outcomes. 
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RESEARCH INFORMATION SHEET 
Title: A randomized controlled trial of Intramuscular Magnesium sulfate in         
          neonates infants with severe Perinatal Asphyxia. 
  Perinatal Asphyxia in the newborn occurs when there is decreased oxygen 
& increased carbon dioxide concentration in the blood around the time of delivery. 
These babies fail to breathe spontaneously at birth & require resuscitation. Severe 
perinatal asphyxia is injurious to the brain and can result in severe neurological 
impairment and death. 
  Injection Magnesium sulphate when given soon after birth seems to have a 
neuroprotective effect in such asphyxiated babies. Animal studies and few studies 
in neonates have shown beneficial effect following intravenous magnesium 
sulphate. The adverse effects following IM Magsulf like hypotension, respiratory 
depression are less likely with the dose used in the study and are manageable in the 
NICU set up.  
  A randomized control trial is being conducted in the Dept of Neonatology 
IOG maternity hospital & Dept. of Neonatology ICH & HC to find out whether IM 
Magnesium sulphate given within 6 hrs of life to severely asphyxiated term babies 
with HIE improves the short term neurological outcome. As your baby was severely 
asphyxiated at birth with HIE we invite you to join in this study. Your baby will 
receive either 3 doses of Intramuscular Magsulf or Placebo (Normal saline) over 
three days as per the study protocol. 
 There is no compulsion. You can withdraw from the trial at anytime during the 
study. Your baby will continue to receive routine care given to an asphyxiated baby 
as per the hospital protocol. During the study, during the analysis of the results and 
during the publication of the study your identity will not be revealed. 
  The outcome of the study will be revealed to you after the completion of 
the study if requested for.  
 
Signature of the Investigator                             Signature of Parent 
Contact Address: 
Dr.C.N.Kamalarathnam 
II yr, D.M. Neonatology post graduate 
I.C.H.&H.C, Egmore, Chennai- 8. 
Mobile No.: 9841102746. 
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 Title: A randomized controlled trial of Intramuscular Magnesium sulfate in 
neonates infants with severe Perinatal Asphyxia. 
 
CONSENT FORM 
I Ms/Mr.__________________________ M/O//F/O, B/O 
_______________________ 
 Sex___________Hosp. No.________________ admitted in the Neonatal 
ICU of IOG/ICH&HC, Egmore on ____________  was explained by the 
doctor that my baby is diagnosed to have “Severe Perinatal Asphyxia “. 
This condition requires Neonatal ICU care. 
I am willing for my child to be enrolled in the Intramuscular Magnesium 
Sulphate trial. The doctors have explained to me the nature and the 
purpose of the trial. 
I have given my consent only after completely understanding the details 
that were explained to me.  
I am willing for my baby to be enrolled in this study without any ones 
compulsion. 
I am fully aware that I can withdraw from the trial at any time during the 
study and routine care for the baby as per the hospital protocol for 
perinatal asphyxia will be continued. 
I have given consent for administering intramuscular Injection of either 
Magnesium sulphate or Saline as per the study protocol.  
I have also given my consent for drawing blood sample for biochemical 
analysis during the study. 
The adverse effects of the drugs were explained to me. 
I have given this consent to be enrolled in this study with my full 
consciousness 
 
 
Signature of the Investigator                                                          Signature 
of parent 
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Place: Chennai -8. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
  
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
no Sl. NO sex gest. Age age in hrs Pl of Del age para DODel mod.of del FHR MSL Late decel Int. part. Compl.
1 A1 2 4 2 2 3 2 4/16/2012 1 4 1 3 1
2 A2 2 4 4 1 2 1 4/18/2012 3 2 1 2 1
3 A3 2 4 4 2 2 1 4/20/2012 1 4 1 3 5
4 A4 2 4 3 1 2 1 4/21/2012 5 2 2 2 1
5 A5 1 4 5 2 3 2 4/25/2012 1 4 2 3 1
6 A6 1 2 5 2 3 2 4/25/2012 3 1 2 2 1
7 A7 2 4 5 2 4 2 4/28/2012 1 4 2 3 1
8 A8 1 4 3 2 2 2 5/2/2012 1 4 2 3 1
9 A9 1 5 3 2 2 1 5/5/2012 5 4 2 3 1
10 A10 2 5 1 1 2 3 5/4/2012 5 2 2 2 1
11 A11 2 5 6 2 2 2 5/9/2012 1 4 1 3 1
12 A12 1 2 2 1 2 2 5/8/2012 5 2 2 2 1
13 A13 1 4 1 1 4 2 5/7/2012 5 4 1 3 1
14 A14 2 3 3 2 2 1 5/27/2012 1 4 2 3 1
15 A15 2 4 1 1 2 1 5/10/2012 1 2 1 2 1
16 A16 1 4 6 1 2 1 5/19/2012 1 2 2 2 1
17 A17 2 4 1 1 3 2 5/25/2012 4 2 2 2 1
18 A18 1 5 1 1 2 1 5/27/2012 1 2 2 2 1
19 A19 2 4 6 2 3 2 5/27/2012 3 3 1 3 1
20 A20 1 1 3 2 2 2 5/29/2012 1 4 2 3 1
21 A21 1 5 4 2 2 1 6/1/2012 1 2 2 2 1
22 A22 1 3 4 1 3 1 6/1/2012 1 2 2 2 1
23 A23 1 4 2 2 2 1 6/8/2012 1 2 1 3 1
24 A24 2 3 3 2 3 1 6/8/2012 1 4 1 3 1
25 A25 2 4 3 2 2 1 6/8/2012 1 4 2 3 1
26 A26 1 4 3 2 2 1 6/14/2012 1 4 2 3 1
27 A27 2 5 3 1 2 1 6/12/2012 1 2 2 2 1
28 A28 1 5 2 1 3 1 6/14/2012 5 2 2 2 1
29 A29 2 4 3 2 1 1 6/15/2012 1 4 2 3 1
30 A30 2 4 3 2 3 1 6/22/2012 1 4 2 3 1
31 A31 1 1 4 2 2 1 6/29/2012 5 4 1 3 1
32 A32 1 5 3 2 2 2 6/26/2012 1 4 2 3 1
33 A33 1 1 5 1 2 1 6/27/2012 1 2 2 2 1
34 A34 1 1 4 2 2 2 6/27/2012 4 4 2 3 1
36 A36 1 5 3 2 3 2 7/5/2012 1 4 2 3 1
37 A37 1 2 4 2 2 1 7/8/2012 1 4 2 3 1
38 A38 1 3 3 1 3 2 7/9/2012 1 2 2 2 1
39 A39 1 4 3 2 3 2 7/10/2012 5 4 2 3 1
40 A40 2 1 1 1 4 2 8/31/2012 1 1 1 1 4
  
 
 
 
no AN Magsulf Dur. LaborO Obstet. Prob Med. Prob B. wt Length wt/ lt-PI OFC-cms apgar 1 apgar 5 apgar 10 resuscitation duration(min)
1 0 1 1 2 3100 48 >2.5 34 1 1
2 0 3 1 2 2850 48 32 2 5 2 1
3 0 3 1 2 2960 49 33.5 2 2 2 3 3
4 0 3 1 2 3015 51 35 2 6 1 1
5 0 1 2 2 3000 49 34 1 2
6 0 1 2 2 2390 48 34 2 6 1 2
7 0 1 2 2 3600 52 34 2 5 1 2
8 0 1 1 2 3250 49 33 2 5 1 1
9 0 2 1 2 2645 48 33 2 5 1 1
10 0 3 1 2 3025 51 32.5 2 4 5 3 2
11 0 1 1 2 2500 47 34 2 1 3
12 0 2 1 2 3330 49 34 2 5 5 1 1
13 0 2 1 2 2500 51 34 2 4 4 3 2
14 0 1 1 2 2200 45 32 2 6 1 1
15 0 2 1 2 2250 49 33.5 1 4 5 3 2
16 0 3 1 2 3250 51 34 2 6 7 1 1
17 0 1 1 2 3750 51 34 0 0 4 3 3
18 0 3 1 2 3350 50 33 3 4 7 1 1
19 0 6 3 2 2400 49 32 3 7 1 1
20 0 1 1 2 4025 53 36 2 1 2
21 0 4 1 2 2970 50 33 2 2 7 1 1
22 0 3 1 2 2750 49 33 2 5 7 1 1
23 0 3 2 2 3000 51 34 2 6 1 1
24 0 2 2 2 2900 52 34 2 1 1
25 0 1 1 2 2750 51 34.5 2 1 2
26 0 6 1 2 3170 50 34 2 4 1 1
27 0 1 1 2 2500 46 32 2 3 7 3 1
28 0 3 1 2 3575 52 36 2 6 7 1 1
29 0 3 1 2 2930 54 33.5 5 1 1
30 0 3 1 2 3250 52 34 2 1 1
31 0 3 1 2 2860 50 34 1 4 7 3 1
32 0 2 1 2 3100 52 34 2 5 1 1
33 0 3 1 2 2250 46 32 1 3 3 2
34 0 5 1 2 2660 53 34 1 3 2
36 0 3 1 2 2980 53 35 3 1 1
37 0 2 1 2 2750 50 34.5 2 5 1 2
38 0 3 1 2 3100 51 33.5 3 5 5 3 2
39 0 3 1 2 2900 50 33.5 1 2 3 3 2
40 0 3 2 2 2000 49 32 0 1 2 3 2
  
 
 
 
no
seizures < 
6hrs HIE
GROUP(drug
) Sr Mg preinj post inj 23 hrs 26hrs 47hrs 50hrs 71hrs
Onset of 
seizure within 
24 hrs
course of 
seizures HIE-D!
1 2 4 0 0.63 1.1 1.2 1.1 1.2 1.08 1 2 1 3
2 2 2 1 1.2 2.25 1.7 3.2 2.5 3 2 1 1 3
3 1 3 0 1.2 1.2 1 3 3
4 1 2 0 1.1 1.2 1 1.2 1.1 1 1 3 2
5 1 3 1 0.9 2.3 2.14 3 1.77 3.5 2.1 2 1 2
6 1 3 1 1.1 3.79 2.67 4 2.47 4 2.59 1 2 3
7 1 2 0 1.2 1.1 1.26 1.3 1.34 1.1 1 3 2
8 1 3 0 1.1 1.2 1.3 1.15 1.2 1 2 3
9 1 2 0 1.1 0.8 0.77 0.73 1.2 0.97 1.2 1 2 2
10 2 3 1 0.77 2.34 2.4 3.25 3.29 2.92 2 1 3
11 1 2 1 0.64 2.5 2.3 2.9 2.45 3 3.2 1 2 2
12 2 2 1 0.78 3.3 2.18 3.6 2.9 3.5 2.8 2 1 2
13 2 2 0 0.73 0.79 1.1 1.2 1.1 1.2 0.98 1 1 2
14 1 2 0 0.9 0.94 0.9 0.8 0.8 0.98 0.9 1 2 2
15 1 2 0 0.77 0.87 0.73 0.64 0.93 0.81 0.94 1 2 2
16 1 2 1 0.68 2.7 2 3.2 2.9 3.9 2.1 1 2 2
17 1 3 1 0.69 2.55 2 1 3
18 1 2 1 0.74 1.97 1.6 2.28 2.1 2.8 1.89 1 2 2
19 1 2 0 0.97 0.88 0.64 0.77 1 2 2
20 1 2 0 0.79 0.89 1.2 1.1 0.81 0.89 0.98 1 3 2
21 1 2 1 0.64 3 1.7 1.8 2 1.8 1 2 2
22 1 2 1 1.1 2.9 2 2.9 1.6 2.7 2.8 1 2 2
23 2 3 0 0.5 0.71 1.1 1 2 1 3
24 2 3 1 0.78 2.2 2.3 2.7 2.6 3 2.7 2 1 3
25 1 2 1 0.75 3.2 3.2 3.7 2.6 1 1 2
26 1 2 0 1.2 1.2 0.9 0.8 1.1 0.9 1.2 2 2 2
27 2 2 1 0.9 2.1 1.5 2.5 1.5 2.5 2 1 1 2
28 1 2 0 0.98 1 0.7 0.7 1.2 1 0.96 1 2 2
29 1 2 0 0.9 0.86 1.2 0.98 1.2 1.1 1 3 2
30 1 2 1 0.98 2.5 2.1 2.6 3.2 1 3 2
31 1 2 0 0.9 1 1 1.2 1.1 2 3 2
32 2 2 1 1.2 3 2 2 2
33 2 3 1 1.2 2.7 2.4 2.9 2 1 3
34 1 2 1 1.2 3.5 2 3.3 2.5 2.1 1 3 3
36 1 2 0 1 0.98 0.74 0.88 1.1 1 2 2
37 1 2 0 1.1 0.98 0.74 1 3 2
38 1 2 0 0.9 1.1 0.9 0.7 0.9 0.8 1 2 2
39 2 3 1 0.74 2.2 2 3.3 2 1 3
40 2 3 0 0.9 1.2 2 1 3
  
 
 
 
no HIE D2 HIE-D3 HIE D4 
onwards
Resp support 
@ Adm
MV after 
24hrs-day4  days of MV
MAP bef Inj 
0hrs MAP aft Inj bef inj 24hrs aft inj 26hrs bef inj 48hrs aft inj 50hrs Shock
1 2 2 3 3 4 44 41 39 40 40 34 1
2 2 2 2 1 2 34 42 38 47 44 45 1
3 3 3 2 30 36 48 42 1
4 2 0 0 1 2 44 48 50 52 48 46 2
5 1 1 0 1 2 43 41 44 41 42 42 2
6 3 1 0 3 2 34 33 44 42 46 44 1
7 3 3 2 2 1 5 54 48 38 54 55 49 2
8 3 3 3 3 4 44 42 38 42 36 34 1
9 2 2 0 2 2 40 42 40 44 44 42 2
10 3 3 2 3 4 44 47 44 46 46 47 1
11 2 3 3 3 5 40 42 47 49 44 53 1
12 2 1 1 2 2 50 48 44 45 46 49 2
13 2 3 3 3 5 36 40 36 34 34 32 1
14 1 1 1 2 2 44 44 42 44 46 44 2
15 2 2 2 3 1 47 46 48 46 46 48 2
16 2 2 0 1 2 42 44 40 42 39 42 2
17 3 1 32 32 1
18 2 2 0 2 2 42 40 48 50 46 44 2
19 1 0 0 1 2 40 45 44 46 42 48 2
20 2 2 2 1 1 2 42 44 42 40 46 48 1
21 2 1 0 2 2 40 44 42 44 46 48 2
22 2 2 0 1 2 48 44 40 44 44 46 2
23 3 3 2 36 38 40 1
24 3 3 3 3 4 30 36 34 35 32 34 1
25 3 2 2 38 40 42 40 2
26 2 3 0 2 1 2 42 44 44 40 40 42 2
27 2 1 0 2 2 46 44 48 46 44 46 2
28 2 1 0 2 2 40 44 42 42 45 42 2
29 2 2 1 2 2 36 42 44 42 44 42 1
30 2 2 2 2 2 32 34 36 38 40 42 1
31 2 2 1 2 2 44 42 40 42 40 42 2
32 2 0 0 1 2 40 44 42 44 2
33 3 3 2 36 40 34 36 1
34 3 3 3 3 8 41 40 43 45 45 44 1
36 2 3 3 2 1 1 44 42 34 32 34 36 1
37 3 3 2 1 1 42 40 40 42 1
38 2 0 0 3 1 41 44 42 44 40 44 2
39 3 3 3 3 30 31 36 38 32 1
40 3 2 0 0 1
  
 
 
 
no Onset treatment 
course
Duration of 
shock
ccf/arrhythmi
a
Hematology Liver 
enzymes GI system metabolic 0 duration start of feeds type
start of 
Paladay/DBF
(days
1 1 2 3 2 2 3 1 6 1 3 0 0
2 1 2 3 2 2 2 1 2 0 0 8 1 15
3 1 2 2 2 1 3 1 2 1 2 0 0
4 0 2 0 3 0 0 0 0 3 1 6
5 0 2 0 3 0 0 0 0 2 2 3
6 1 2 2 2 0 3 0 0 0 0 3 1 4
7 0 2 0 3 0 0 1 1 5 1 10
8 2 3 4 2 1 3 0 4 1 3 0 0
9 0 2 0 3 0 0 0 0 2 1 5
10 1 2 3 2 0 3 0 0 1 2 5 1 19
11 2 2 3 2 1 3 1 4 1 2 8 1 25
12 0 2 2 3 0 0 0 0 2 1 6
13 1 2 4 2 2 3 0 1 1 2 0 0
14 0 2 2 3 3 0 1 2 3 1
15 0 2 2 3 0 0 0 0 4 1 9
16 0 2 2 3 0 0 0 0 3 2 4
17 1 3 1 1 2 3 1 4 1 1 0 0
18 0 2 2 3 0 4 0 0 3 1 5
19 0 2 2 3 0 0 0 0 2 2 4
20 2 2 3 2 2 3 0 2 1 1 2 1 16
21 0 2 2 3 0 0 0 0 3 2 5
22 0 2 2 3 0 0 0 0 3 2 5
23 1 2 1 2 2 3 1 6 1 1 0 0
24 1 2 3 2 2 3 1 6 1 1 0 0
25 0 2 2 3 1 0 0 0 2 1
26 0 2 1 3 1 0 0 0 3 1 4
27 0 2 2 3 0 0 0 0 3 2 4
28 0 2 2 3 0 0 0 0 3 2 5
29 1 2 1 2 2 3 0 0 0 0 3 1 4
30 1 2 2 1 2 3 0 0 1 2 4 1
31 0 2 2 3 0 0 1 1 3 1 5
32 0 2 2 3 0 0 0 0 2 2 3
33 1 2 2 2 0 3 0 5 1 2 0 0
34 1 2 3 1 1 2 1 5 1 3 7 1 28
36 2 2 2 2 2 3 0 3 1 1 0 0
37 2 2 2 2 2 3 0 4 0 0 0 0
38 0 2 2 3 0 1 0 0 3 2 4
39 1 2 3 2 2 3 0 4 2 2 0 0
40 1 3 2 2 2 3 1 5 0 0 0 0
  
 
 
 
no Death Death/survival with abn ne Outcome
age at 
discharge(day
s)
NE @ 
Dis/D14 CT U/S-Cr MRI EEG
1 1 1 1 3 3 4 3
2 2 2 2 19 2 3 2 4 3
3 1 1 1 3 3 4 3
4 2 2 2 7 1 3 1 4 3
5 2 2 2 6 1 3 1 4 3
6 2 2 2 6 1 3 3 4 3
7 2 2 2 8 1 3 1 4 3
8 1 1 1 3 3 4 3
9 2 2 2 7 1 3 2 4 3
10 2 2 2 19 1 3 1 4 3
11 2 1 3 25 2 2 2 4 3
12 2 2 2 8 1 3 1 4 3
13 1 1 1 3 3 4 3
14 1 1 1 3 1 4 3
15 2 1 3 15 2 2 1 4 3
16 2 2 2 6 1 3 1 4 3
17 1 1 1 3 3 4 3
18 2 2 2 9 1 3 2 4 3
19 2 2 2 4 1 3 3 4 3
20 2 1 3 16 2 3 2 4 3
21 2 2 2 7 1 3 1 4 3
22 2 2 2 8 1 3 1 4 3
23 1 1 1 3 3 4 3
24 1 1 1 3 3 4 3
25 1 1 1 3 3 4 3
26 2 2 2 6 1 3 1 4 3
27 2 2 2 8 1 3 1 3 3
28 2 2 2 8 1 3 1 4 3
29 2 2 2 7 1 3 1 4 3
30 1 1 1 3 3 4 3
31 2 2 2 6 1 3 1 4 3
32 2 2 2 3 1 3 3 4 3
33 1 1 1 3 3 4 3
34 2 1 3 31 1 2 4 3
36 1 1 1 3 3 4 3
37 1 1 1 3 3 4 3
38 2 2 2 5 1 3 1 4 3
39 1 1 1 3 3 4 3
40 1 1 1 3 3 4 3
  
 
 
 
no Sl. NO sex gest. Age age in hrs Pl of Del age para DODel mod.of del FHR MSL Late decel Int. part. Compl.
41 A41 1 4 3 2 2 1 7/11/2012 1 4 2 3 1
42 A42 1 3 6 2 2 2 8/8/2012 1 1 2 3 1
43 A43 1 5 4 2 2 1 8/9/2012 1 4 1 3 1
44 A44 1 4 5 2 2 1 8/19/2012 1 4 2 3 1
45 A45 1 2 5 2 2 1 8/21/2012 1 4 2 3 1
46 A46 2 5 6 2 2 1 9/3/2012 1 4 1 3 1
47 A47 1 2 6 2 4 1 9/18/2012 1 4 1 3 1
48 A48 1 3 6 2 2 1 10/2/2012 1 4 2 3 1
49 A49 2 4 2 2 2 1 10/8/2012 1 4 2 2 1
50 A50 2 4 3 2 4 2 10/9/2012 1 4 2 3 1
51 A51 1 4 4 2 3 1 10/9/2012 1 4 2 3 1
52 A52 1 4 6 2 2 1 10/9/2012 3 4 1 3 1
53 A53 2 1 4 1 2 2 10/12/2012 1 1 1 2 1
54 A54 2 3 4 2 3 2 10/12/2012 1 4 2 3 1
55 A55 2 4 4 2 3 2 10/11/2012 1 4 2 2 1
56 A56 1 3 5 1 2 2 10/18/2012 1 2 2 2 1
57 A57 2 5 4 2 2 1 10/22/2012 3 2 1 3 1
58 A58 1 5 3 2 2 1 11/10/2012 1 4 2 3 1
59 A59 1 5 3 2 1 1 10/20/2012 1 4 2 3 1
60 A60 2 5 5 2 1 1 10/29/2012 1 4 2 3 1
61 A61 1 3 6 2 2 1 11/1/2012 1 4 2 3 1
62 A62 1 5 6 2 2 1 11/4/2012 1 4 1 3 1
63 A63 2 4 5 2 2 1 11/7/2012 5 4 1 3 1
64 A64 2 4 6 1 2 1 11/7/2012 5 2 2 2 1
65 A65 1 5 6 2 2 1 11/13/2012 1 4 1 3 1
66 A66 1 5 5 1 2 1 11/11/2012 3 2 1 2 1
67 A67 1 1 5 1 2 1 11/15/2012 5 2 1 2 1
68 A68 1 4 6 1 2 1 11/16/2012 5 2 1 3 1
69 A69 1 4 6 2 2 1 11/16/2012 1 4 2 3 1
70 A70 1 5 5 2 3 2 11/17/2012 1 4 2 3 1
71 A71 2 3 6 2 2 2 11/18/2012 1 4 2 3 1
72 A72 1 5 5 2 2 1 11/19/2012 3 4 1 3 1
73 A73 2 5 4 2 2 1 11/22/2012 1 4 1 3 1
74 A74 1 4 4 2 2 1 11/23/2012 5 4 2 3 1
75 A75 1 5 4 1 3 1 11/25/2012 3 1 2 1 1
76 A76 1 4 4 2 2 2 11/25/2012 1 4 2 3 1
77 A77 1 5 2 2 4 1 11/26/2012 1 4 1 3 1
78 A78 1 5 6 2 2 1 12/1/2012 5 4 2 3 1
  
 
 
 
no AN Magsulf Dur. LaborO Obstet. Prob Med. Prob B. wt Length wt/ lt-PI OFC-cms apgar 1 apgar 5 apgar 10 resuscitation duration(min)
41 0 3 1 2 2225 49 33 2 5 6 1 2
42 0 3 1 2 2500 51 34 1 3 1 1
43 0 3 1 2 3000 51 33 3 4 5 1 2
44 0 3 1 2 2500 51 33.5 2 5 1 1
45 0 2 1 2 2670 49 33.5 2 5 1 1
46 0 6 1 2 3000 53 34 2 3 1 1
47 0 3 1 2 2300 51 33 1 1
48 0 3 1 2 2800 51 34.5 2 5 1 1
49 0 2 1 2 2300 52 33 2 5 1 1
50 0 3 1 2 2030 45 32 2 5 1 1
51 0 3 1 2 2900 50 34.5 2 1 1
52 0 3 1 2 2750 51 33 2 6 1 1
53 0 3 2 2 2000 47 33 2 2 4 2 2
54 0 1 1 2 3000 52 33.5 2 1 2
55 0 3 1 2 3700 54 35 2 3 3 2
56 0 3 1 2 3125 51 34 3 5 6 3 1
57 0 1 1 2 3000 50 34 2 5 5 3 2
58 0 3 1 2 3050 49 33.5 2 3 5 3 3
59 0 2 1 2 3010 51 34 2 3 5 1 2
60 0 3 1 2 2600 49 33.5 2 5 1 1
61 0 2 1 2 2600 50 33 2 5 3 2
62 0 2 1 2 3200 49 33 2 1 1
63 0 2 1 2 2860 50 33 2 5 1 1
64 0 2 1 2 2580 49 33.5 2 7 3 1
65 0 3 1 2 2793 50 34 3 2 2
66 0 3 1 2 2500 54 30 2 4 6 3 2
67 0 3 2 2 2100 45.5 32 3 5 6 3 1
68 0 2 1 2 2800 52 34 3 4 6 2 2
69 0 2 1 2 2500 59 34 2 4 1 2
70 0 3 1 2 3000 50 36 2 4 2 2
71 0 3 1 2 2370 49 33.5 1 1
72 0 3 1 2 3250 50 34 2 4 3 2
73 0 3 1 2 3200 54 34 1 5 5 1 1
74 0 3 1 1 2820 52 33 2 5 1 1
75 0 2 1 2 3125 55 35 2 4 4 3 2
76 0 1 1 1 2960 52 33.5 2 4 1 1
77 0 2 1 2 2680 52 34 2 4 1 2
78 0 3 1 2 3250 51 35 2 1 1
  
 
 
 
no
seizures < 
6hrs HIE
GROUP(drug
) Sr Mg preinj post inj 23 hrs 26hrs 47hrs 50hrs 71hrs
Onset of 
seizure within 
24 hrs
course of 
seizures HIE-D!
41 1 2 1 0.94 2.4 2.2 1.9 1 2 2
42 1 2 1 0.9 1.8 0.8 1.6 1.8 2.6 1.8 1 2 2
43 2 2 1 1.1 2.4 1.1 1.8 1.8 1.9 1.7 2 1 2
44 1 2 0 1.2 0.98 0.9 1 0.7 1.1 0.8 1 2 2
45 1 2 0 1.2 1.1 0.9 0.86 0.94 0.5 1 2 2
46 1 2 1 1 2.3 1.3 1.7 1.8 2 1.8 1 3 2
47 1 2 1 0.8 1.3 1.2 1.9 1.8 2.2 1.9 1 3 2
48 1 2 0 0.4 0.5 1.2 1.4 0.8 0.5 0.5 1 2 2
49 1 2 0 1.1 1.2 1.2 1.1 1 1.2 1 2 2
50 1 2 0 0.7 1.2 0.98 0.94 1.1 0.96 0.64 1 3 2
51 1 2 1 0.7 1.9 1.3 2.2 2.8 2 1 3 2
52 1 2 1 0.9 2 1.5 2.1 2.3 2.8 2.1 1 3 2
53 1 3 1 1.1 2.9 1.7 2.2 2.7 1.6 1 2 2
54 1 2 0 1.1 0.89 0.98 1.1 0.69 0.96 1 2 2
55 2 3 1 1.1 2.5 1 2 3
56 1 2 1 0.98 1.6 2.5 1.8 2.9 1.9 1 2 2
57 2 3 0 0.76 0.96 0.78 0.74 0.76 0.8 2 2 3
58 1 2 0 1 0.69 0.7 0.68 0.72 0.84 0.64 1 3 2
59 2 3 0 1.1 1 1 0.9 1.1 2 1 3
60 1 2 1 1.1 2.6 1.8 1.5 2.6 1 2 2
61 1 2 0 0.6 1.1 0.6 0.6 0.8 1.1 1 2 2
62 1 2 1 0.9 2.1 1.6 2 1.8 2.6 1 2 2
63 2 2 1 0.9 1.9 1.6 2 1.3 3.1 2 1 2
64 1 2 0 1 1.1 1.1 1.2 1 2 2
65 2 3 0 1.1 0.96 1.2 2 1 3
66 2 3 1 1.9 3 2.4 2.9 2.5 2.5 2.3 2 1 2
67 1 2 0 1 0.93 0.9 1.1 1 1 2 2
68 2 2 1 1.1 2.5 1.7 2.4 2.4 1 2 3
69 2 2 0 0.92 1.1 0.94 1 1.2 1.1 1 1 2 2
70 2 3 1 1 1.9 1.8 2 1 3
71 1 2 0 0.89 0.92 0.7 1.1 0.95 1.1 1 3 2
72 2 3 1 1.1 1.7 2 1 3
73 1 2 0 1.1 0.98 1.1 0.99 0.98 1 2 2
74 2 2 1 0.98 3 1.2 1.9 1.7 1.9 2 1 2
75 1 3 0 1 1.1 0.7 0.6 0.7 0.7 0.8 1 2 3
76 1 2 0 1.2 1.2 1.1 1 0.9 0.94 1 2 2
77 1 2 1 1 2.2 1.3 2.5 1.6 2.4 1 2 2
78 1 2 1 1.2 2 1.6 2.5 1.7 2.3 1.8 1 2 2
  
 
 
 
no HIE D2 HIE-D3 HIE D4 
onwards
Resp support 
@ Adm
MV after 
24hrs-day4  days of MV
MAP bef Inj 
0hrs MAP aft Inj bef inj 24hrs aft inj 26hrs bef inj 48hrs aft inj 50hrs Shock
41 2 1 0 2 2 36 42 40 44 42 46 1
42 2 2 3 3 8 43 42 42 42 43 42 1
43 3 3 3 2 1 4 44 78 56 58 54 52 1
44 2 2 3 3 4 45 44 42 43 42 56 1
45 2 1 1 2 2 39 41 43 46 45 46 2
46 2 2 2 2 1 4 39 54 34 50 40 44 1
47 2 2 0 2 2 31 37 34 44 44 45 1
48 2 2 2 1 2 42 40 42 42 40 33 1
49 2 0 0 1 2 44 44 45 42 44 40 2
50 2 3 3 2 1 4 44 40 36 39 36 39 1
51 2 2 2 1 2 55 53 45 42 45 42 2
52 2 3 3 2 1 3 42 44 40 42 26 27 1
53 2 2 3 3 7 42 43 44 44 29 26 1
54 2 2 0 2 2 42 39 44 44 44 42 2
55 3 3 2 30 33 27 29 1
56 2 0 0 1 2 44 45 44 45 42 44 2
57 3 3 3 3 7 36 40 52 50 51 50 1
58 2 2 2 2 2 44 43 46 42 47 46 2
59 3 3 3 4 32 46 40 47 32 36 1
60 2 2 2 2 2 33 40 45 46 44 48 1
61 2 2 2 2 1 4 51 55 42 41 38 40 1
62 3 3 3 2 1 3 40 40 33 53 36 38 1
63 2 0 0 2 2 35 39 45 48 44 46 1
64 2 2 0 1 2 44 46 40 39 42 44 2
65 3 3 2 40 40 32 30 1
66 2 0 0 3 2 42 40 40 45 40 42 2
67 3 42 44 39 40 2
68 3 3 3 42 44 40 42 1
69 0 0 0 1 2 42 46 44 42 40 45 2
70 3 3 3 36 34 30 32 1
71 2 3 3 2 1 8 42 46 32 36 44 40 1
72 3 2 42 36 1
73 2 0 0 1 2 54 52 52 52 52 51 2
74 2 2 2 2 2 44 41 45 43 44 43 2
75 3 3 3 3 36 40 44 44 36 1
76 2 2 2 2 2 35 34 40 46 44 43 1
77 2 2 2 2 2 49 46 44 42 40 44 2
78 2 2 0 2 2 46 44 35 44 45 46 1
  
 
 
 
no Onset treatment 
course
Duration of 
shock
ccf/arrhythmi
a
Hematology Liver 
enzymes GI system metabolic 0 duration start of feeds type
start of 
Paladay/DBF
(days
41 1 2 2 2 2 3 0 0 0 0 3 2 4
42 1 2 2 1 2 3 0 1 0 0 0 0
43 1 2 2 1 2 3 0 4 1 2 0 0
44 2 2 4 2 2 3 0 4 1 3 0 0
45 0 2 2 3 0 2 0 0 3 2 4
46 1 2 2 2 2 3 0 2 0 0 7 1 12
47 1 2 2 2 2 3 0 0 0 0 3 1 5
48 2 2 3 2 1 3 0 5 1 2 3 1 14
49 0 2 2 3 0 0 0 0 3 3 3
50 1 3 4 1 1 3 1 6 1 2 0 0
51 0 2 2 3 0 5 1 2 5 1 9
52 2 2 3 2 2 3 0 6 1 2 0 0
53 1 2 4 2 2 3 0 6 0 0 0 0
54 0 2 2 3 0 0 0 0 3 1 4
55 1 3 2 1 2 3 1 6 1 2 0 0
56 0 2 2 3 0 0 0 0 3 2 3
57 1 2 2 2 2 3 1 5 1 3 0 0
58 0 2 2 3 0 0 0 0 3 1 6
59 1 3 4 2 2 3 0 2 0 0 0 0
60 1 2 2 2 2 3 0 0 0 0 3 1 5
61 1 2 3 2 2 3 0 0 0 0 6 1 8
62 1 2 4 2 2 3 0 0 1 2 0 0
63 1 2 2 2 2 3 0 0 0 0 4 1 5
64 0 2 2 3 0 0 0 0 3 1 5
65 1 2 2 2 2 3 1 6 1 1 0 0
66 0 2 2 3 0 0 0 0 4 1 5
67 0 2 2 3 1 0 0 2 0 0
68 2 2 2 2 2 3 0 0 1 1 0 0
69 2 0 2 2 3 0 0 0 0 2 3 3
70 1 2 3 2 1 3 0 5 1 2 0
71 2 2 2 2 2 3 1 5 1 3 8 1 22
72 1 2 2 2 2 3 1 6 1 1 0 0
73 0 2 2 3 0 0 0 0 2 1 4
74 0 2 2 3 0 6 0 0 3 1 8
75 1 2 3 1 2 3 0 6 1 2 0 0
76 1 2 2 2 2 3 0 6 0 0 4 1 6
77 0 2 2 3 0 0 0 0 3 1 5
78 2 2 2 2 2 3 1 0 0 0 3 1 5
  
 
 
 
no Death Death/survival with abn ne Outcome
age at 
discharge(day
s)
NE @ 
Dis/D14 CT U/S-Cr MRI EEG
41 2 2 2 6 1 3 1 4 3
42 2 1 4 8 2 2 2 4 3
43 1 1 1 3 3 4 3
44 1 1 1 3 3 4 3
45 2 2 2 5 1 3 1 4 3
46 2 1 3 14 2 3 2 4 3
47 2 2 2 7 1 3 2 4 3
48 2 1 3 10 2 3 2 4 3
49 2 2 2 3 1 3 1 4 3
50 1 1 1 3 3 4 3
51 2 1 3 10 1 3 2 4 3
52 1 1 1 3 3 4 3
53 1 1 1 3 3 4 3
54 2 2 2 6 1 3 2 4 3
55 1 1 1 3 3 4 3
56 2 1 3 7 1 3 1 4 3
57 1 1 1 3 3 4 3
58 2 2 2 7 1 3 3 4 3
59 1 1 1 3 3 4 3
60 2 2 2 6 1 3 1 4 3
61 2 2 2 8 1 3 1 4 3
62 1 1 1 3 3 4 3
63 2 2 2 6 1 3 2 4 3
64 2 2 2 6 1 3 1 4 3
65 1 1 1 3 3 4 3
66 2 2 2 6 1 3 1 4 3
67 1 1 1 3 3 4 3
68 1 1 1 3 3 4 3
69 2 2 2 4 1 3 1 4 3
70 1 1 1 3 3 4 3
71 2 1 3 30 2 3 2 4 3
72 1 1 1 3 3 4 3
73 2 2 2 6 1 3 1 4 3
74 2 2 2 9 1 3 2 4 3
75 1 1 1 3 3 4 3
76 2 2 2 7 1 3 1 4 3
77 2 2 2 8 1 3 1 4 3
78 2 2 2 8 1 3 2 4 3
  
 
 
 
no Sl. NO sex gest. Age age in hrs Pl of Del age para DODel mod.of del FHR MSL Late decel Int. part. Compl.
79 A79 1 2 5 2 2 2 11/27/2012 1 4 1 3 1
80 A80 1 5 3 2 2 1 12/1/2012 3 2 2 2 1
81 A81 1 2 5 2 1 1 12/7/2012 3 4 2 3 1
82 A82 2 5 5 2 2 1 12/10/2012 1 4 1 3 1
83 A83 1 5 5 2 2 1 12/10/2012 1 4 1 3 1
84 A84 1 5 6 2 3 2 12/10/2012 1 4 2 3 1
85 A85 1 5 4 2 2 1 11/17/2012 1 4 2 3 1
86 A86 1 2 4 2 2 1 12/17/2012 1 4 2 3 1
87 A87 2 2 4 2 2 1 12/19/2012 1 4 1 3 1
88 A88 1 4 5 2 2 1 12/19/2012 1 4 1 3 1
89 A89 1 2 4 2 3 2 12/20/2012 1 4 1 3 1
90 A90 1 3 5 1 2 1 12/24/2012 2 2 2 2 1
91 A91 1 5 5 2 3 2 12/27/2012 1 4 2 3 1
92 A92 2 5 4 2 2 1 12/30/2012 1 4 1 3 1
93 A93 2 4 5 1 3 1 12/31/2012 5 2 2 2 1
94 A94 1 3 3 2 2 1 1/3/2013 1 4 1 3 1
95 A95 1 5 4 2 2 1 1/4/2013 1 4 2 3 1
96 A96 2 3 3 2 2 1 1/9/2013 1 4 1 3 1
97 A97 2 5 6 2 3 2 1/3/2013 1 4 2 3 1
98 A98 1 3 5 2 2 1 1/12/2013 1 4 1 3 1
99 A99 2 2 3 2 3 1 1/12/2013 1 4 2 3 1
101 A101 2 5 5 2 2 1 1/14/2013 1 4 2 3 1
102 A102 2 4 3 1 2 1 1/15/2013 5 1 2 1
103 A103 2 4 6 2 2 1 1/14/2013 1 4 2 3 1
104 A104 1 5 5 1 2 1 1/15/2013 3 2 1 2 5
105 A105 1 4 5 2 2 1 1/18/2013 1 4 2 3 1
106 A106 1 5 5 1 5 2 1/27/2013 3 2 1 2 1
107 A107 1 3 4 2 2 1 1/27/2013 1 4 1 3 1
108 A108 1 3 5 2 2 1 1/25/2013 1 4 1 3 1
109 A109 2 4 4 1 3 1 1/25/2013 3 2 1 2 1
110 A110 1 3 5 1 3 1 1/29/2013 1 2 2 2 1
111 A111 2 2 3 1 4 2 1/29/2013 3 2 2 1 1
112 A112 1 3 5 1 2 1 1/31/2013 1 2 2 2 5
113 A113 2 5 5 2 2 1 2/19/2013 1 4 1 3 1
115 A115 1 1 2 1 3 1 2/19/2013 3 2 2 2 1
116 A116 1 1 2 1 3 1 2/19/2013 1 2 2 2 1
117 A117 2 3 5 2 2 1 2/20/2013 1 4 1 3 1
118 A118 2 2 2 1 2 1 2/22/2013 5 2 1 2 1
119 A119 2 4 6 1 2 2 2/22/2013 3 2 1 2 1
  
 
 
 
no AN Magsulf Dur. LaborO Obstet. Prob Med. Prob B. wt Length wt/ lt-PI OFC-cms apgar 1 apgar 5 apgar 10 resuscitation duration(min)
79 0 1 1 2 3500 51 34 2 5 1 1
80 0 3 1 2 2730 51 34 0 3 5 1 1
81 0 5 1 2 3300 51.5 3 2 5 5 1 1
82 0 2 1 2 3300 51 35 2 6 1 1
83 0 3 1 2 2500 53 34 2 4 1 1
84 0 3 1 2 3000 50 35 2 5 1 1
85 0 3 1 2 3150 51 34 2 6 1 1
86 0 2 1 2 2250 49 32 2 5 1 1
87 0 3 1 2 2850 49 33 2 4 1 2
88 0 5 1 2 3080 50 35 2 1 1
89 0 2 1 2 2800 51 35 2 5 1 2
90 0 6 1 2 2750 52 34 2 3 5 3 2
91 0 2 1 2 3600 52 36 2 6 1 1
92 0 3 1 2 2850 51 33.5 1 1
93 0 3 1 2 3200 49 36 2 5 6 3 1
94 0 3 1 2 2250 48 32 1 1
95 0 2 1 2 3000 53 35 1 1
96 0 3 1 2 2500 53 34 1 1
97 0 1 1 2 3000 51 34 1 1
98 0 2 1 2 2488 49 33 2 1 1
99 0 2 1 2 3070 50 35 2 6 1 1
101 0 3 1 8 2830 51 35.5 2 5 3 1
102 0 3 1 8 3040 51 33 2 5 6 1 1
103 0 3 1 8 2420 49 33 2 5 3 2
104 0 3 1 8 2665 52 35 2 5 7 2 1
105 0 5 1 8 3250 49 34 2 4 5 1 1
106 0 3 1 2 3700 54 35 2 5 7 1 1
107 0 2 1 8 3000 53 35 2 5 1 3
108 0 5 1 8 3140 51 34 1 1
109 0 3 1 8 2280 49 32 1 3 5 3 1
110 0 3 1 8 3000 49 33 2 5 7 3 1
111 0 3 1 8 3250 51 32 1 4 6 3 1
112 0 4 1 8 2200 49 31.5 2 5 6 2 1
113 0 3 1 8 2480 49 33 2 1 1
115 0 3 4 8 2150 47 32 2 6 1 1
116 0 3 4 8 2320 49 33 2 6 7 1 1
117 0 3 4 8 3100 51 34 1 1
118 0 3 1 8 2400 49 33 2 5 5 3 1
119 0 3 2 8 1960 48 32 2 5 6 1 1
  
 
 
 
no
seizures < 
6hrs HIE
GROUP(drug
) Sr Mg preinj post inj 23 hrs 26hrs 47hrs 50hrs 71hrs
Onset of 
seizure within 
24 hrs
course of 
seizures HIE-D!
79 1 2 1 0.9 1.7 1.5 1.6 2.1 2.1 1 2 2
80 2 2 0 1.2 0.82 1.1 1.2 0.96 2 1 2
81 1 2 0 0.9 1.2 0.8 0.7 0.6 0.8 1 3 2
82 1 2 1 1.1 1.3 1.5 2.2 2.3 2.2 1 2 2
83 2 2 1 1.1 1.7 1.7 1.4 1.9 2 1 2
84 2 2 0 1.1 1.2 1 1.1 0.8 1.2 1 3 2
85 2 2 1 0.9 3.1 1.7 2.7 1.2 2.1 2.2 2 1 2
86 2 2 0 0.5 1 0.7 0.7 1 2 1 2
87 2 3 0 0.9 2 1 3
88 1 2 1 1.1 2 1.6 3.2 1.6 3.2 1.6 1 3 2
89 2 3 0 0.8 0.9 2 1 3
90 2 2 1 1.2 3.2 2.8 3.2 2.5 3 2 1 3
91 1 2 0 0.7 0.7 1 0.6 0.6 1.1 0.9 1 3 2
92 1 2 1 1.2 2.9 1.9 2.4 1.5 2.5 1 3 2
93 1 2 0 0.7 0.8 0.8 1.1 1.2 0.9 1 2 2
94 2 2 0 1.1 1.1 1.2 0.9 1.1 1.2 2 1 2
95 1 2 1 1.2 2.2 1.8 2.3 2 3 1 2 2
96 1 2 1 0.9 2.1 3 1.7 2.3 1.7 1 3 2
97 1 2 0 0.9 1.1 1.2 1 0.8 1.2 1.2 1 2 3
98 1 2 1 1.2 2.6 1.8 1 2 2
99 1 2 0 1.1 0.89 1.1 1 1.2 1.2 1.1 1 2 2
101 1 2 1 1.1 3 1.3 2.3 1.2 2 1.2 1 2 2
102 1 2 1 0.8 1.5 0.7 1.8 1 1.5 1 2 2
103 1 2 0 1.1 0.9 0.86 1.2 1.1 1.1 1 2 2
104 2 2 0 1.1 1.03 0.94 0.9 0.7 1 1 2 2
105 1 2 0 1.1 0.86 0.87 0.78 0.65 0.98 0.78 1 2 2
106 1 2 1 1.1 2.4 1.2 2.3 1.3 3 2.14 1 2 2
107 1 2 1 1.1 2.2 2 2.97 1.64 2.34 2 1 3 3
108 1 2 1 1.1 2 1.6 2.35 1.6 1.31 1 3 3
109 2 2 0 1 1.2 0.78 0.82 1.2 1.1 1 2 1 2
110 2 2 0 1.07 1.04 0.75 0.82 1.1 1.15 1 1 2 2
111 2 2 0 0.53 0.86 1 0.78 0.78 2 1 2
112 1 2 1 0.8 1.6 1.5 2.6 1 2 3
113 1 2 1 0.53 1.6 1.55 1 2 3
115 1 2 0 0.65 0.45 0.49 0.61 0.74 0.53 0.65 1 2 2
116 1 2 0 0.57 0.4 0.61 0.61 0.49 0.61 0.4 1 2 2
117 1 2 1 0.61 2.3 1.7 2.06 1.52 1.45 1 3 2
118 1 2 1 1.06 2 1.5 2.26 1.45 2.2 1.5 1 2 2
119 1 2 0 1.03 1.05 0.9 1.03 0.94 0.94 1 2 2
  
 
 
 
no HIE D2 HIE-D3 HIE D4 
onwards
Resp support 
@ Adm
MV after 
24hrs-day4  days of MV
MAP bef Inj 
0hrs MAP aft Inj bef inj 24hrs aft inj 26hrs bef inj 48hrs aft inj 50hrs Shock
79 2 3 3 2 1 6 32 40 53 52 44 48 1
80 2 0 0 1 2 42 42 44 43 42 43 2
81 2 2 3 2 1 1 50 52 42 40 48 44 1
82 2 2 2 2 2 35 39 35 39 40 44 1
83 2 2 2 2 2 48 46 47 50 46 48 2
84 3 3 2 3 3 46 33 54 56 4 46 1
85 2 0 0 2 2 44 42 44 42 40 42 2
86 2 2 0 2 2 42 42 42 40 46 52 2
87 3 1 32 0 1
88 2 2 2 2 2 40 42 52 50 49 50 2
89 3 3 2 34 36 1
90 3 3 3 3 3 38 45 52 54 28 28 1
91 3 3 2 2 1 2 42 30 39 42 44 46 1
92 2 3 3 2 1 2 42 44 58 52 56 54 1
93 2 2 0 2 2 44 56 44 44 42 42 2
94 2 0 0 2 2 44 44 42 40 44 42 1
95 2 3 3 2 1 3 35 44 54 56 55 54 1
96 2 2 2 1 2 34 40 38 40 41 42 1
97 3 3 3 3 8 44 42 42 44 40 39 1
98 3 2 1 2 40 41 65 57 2
99 2 2 0 1 2 42 44 44 40 42 40 2
101 2 2 2 2 1 3 46 46 48 42 44 45 1
102 2 2 0 2 2 42 46 45 44 46 48 2
103 2 3 3 2 1 8 41 44 40 42 37 38 1
104 2 2 3 2 1 2 34 37 46 44 46 48 1
105 2 1 0 2 2 37 42 44 46 42 44 1
106 2 2 3 3 5 44 46 44 42 40 44 1
107 3 3 3 3 5 37 39 40 38 42 44 2
108 3 2 2 3 3 35 43 44 42 44 46 1
109 2 2 0 3 2 44 41 48 44 46 51 2
110 2 2 0 3 1 54 55 53 53 52 54 2
111 2 2 2 2 35 55 55 52 38 36 1
112 3 3 3 41 41 40 36 1
113 3 3 3 50 52 33 35 0 1
115 2 2 0 3 1 38 39 40 36 42 40 2
116 2 2 0 2 2 37 36 39 44 40 42 2
117 2 3 3 3 5 31 38 38 42 53 44 2
118 2 2 2 3 8 36 42 42 40 39 40 1
119 2 2 2 3 1 44 42 42 46 44 46 2
  
 
 
 
no Onset treatment 
course
Duration of 
shock
ccf/arrhythmi
a
Hematology Liver 
enzymes GI system metabolic 0 duration start of feeds type
start of 
Paladay/DBF
(days
79 1 2 4 1 2 3 1 6 0 0 0 0
80 0 2 2 3 0 0 0 0 2 2 4
81 2 2 2 2 1 3 1 3 1 2 0 0
82 1 1 1 2 1 3 0 5 0 0 3 1 8
83 0 2 2 3 3 5 0 0 6 1 8
84 2 2 2 2 2 3 0 6 0 0 6 1 8
85 0 2 2 3 0 0 0 0 1 1 3
86 0 2 2 3 0 0 0 0 2 1 3
87 1 3 1 2 2 3 1 6 0 0 0 0
88 0 0 2 2 3 0 0 0 0 2 1
89 1 2 2 2 2 3 0 6 1 1 0 0
90 1 2 2 2 1 3 1 6 0 0 0 0
91 1 2 2 2 2 3 1 6 1 3 4 1 9
92 2 2 3 2 2 3 1 7 2 1 0 0
93 0 0 2 2 3 0 0 0 0 2 1 6
94 0 0 2 2 3 0 0 0 0 2 2 3
95 1 2 2 2 2 3 0 0 0 0 3 1 0
96 1 2 3 2 2 3 0 0 0 0 4 1 10
97 1 2 3 2 2 3 0 7 1 1 3 1 18
98 0 2 2 3 0 6 1 1 0 0
99 0 2 2 3 0 0 0 0 2 1 6
101 1 2 2 2 2 3 0 0 0 0 5 1 11
102 0 2 2 3 0 0 0 0 2 2 4
103 2 2 4 1 2 3 1 6 1 3 1 0
104 1 2 3 2 2 3 2 4 1 2 0 0
105 1 2 1 2 2 3 0 0 0 0 2 2 3
106 3 2 3 2 2 3 0 4 1 3 4 1 14
107 2 2 2 3 0 6 1 2 5 1
108 1 2 2 2 1 3 0 6 0 0 5 1 8
109 0 1 2 3 0 6 0 0 3 1 6
110 0 2 2 3 0 0 0 0 2 1 5
111 2 2 3 2 2 3 1 0 0 0 0 0
112 1 2 3 2 2 3 1 6 0 0 0 0
113 2 3 2 2 2 3 0 6 1 1 0 0
115 0 2 2 3 0 0 0 0 3 2 4
116 0 2 2 3 0 1 0 0 4 2 4
117 0 2 2 3 0 0 0 0 7 1 12
118 1 2 4 2 1 3 0 0 1 3 0 0
119 0 2 2 3 0 1 0 0 4 1 7
  
 
 
 
no Death Death/survival with abn ne Outcome
age at 
discharge(day
s)
NE @ 
Dis/D14 CT U/S-Cr MRI EEG
79 1 1 1 2 3 4 3
80 2 2 2 4 1 3 2 4 3
81 1 1 1 3 3 4 3
82 2 2 2 9 1 3 2 4 3
83 2 2 2 22 1 3 1 4 3
84 2 1 3 10 2 3 2 4 3
85 2 2 2 5 2 3 3 4 3
86 2 2 2 6 1 3 2 4 3
87 1 1 1 3 3 4 3
88 1 1 1 3 2 4 3
89 1 1 1 3 3 4 3
90 1 1 1 3 3 4 3
91 2 2 2 14 1 3 2 4 3
92 1 1 1 3 3 4 3
93 2 1 3 10 2 2 1 4 3
94 2 2 2 4 1 3 1 4 3
95 1 1 1 3 3 4 3
96 2 2 2 14 1 3 2 4 3
97 2 1 3 21 2 2 2 4 3
98 1 1 1 3 3 4 3
99 2 2 2 7 1 3 1 4 3
101 2 1 3 14 2 3 2 4 3
102 2 2 2 6 1 3 1 4 3
103 1 1 1 3 3 4 3
104 1 1 1 3 3 4 3
105 2 2 2 6 1 3 1 4 3
106 2 2 2 14 1 3 2 4 3
107 1 1 1 3 3 4 3
108 2 1 3 12 2 3 1 3 3
109 2 2 2 7 1 3 1 4 3
110 2 2 2 8 1 3 2 4 3
111 1 1 1 3 3 4 3
112 1 1 1 3 3 4 3
113 1 1 1 3 3 4 3
115 2 2 2 9 1 3 1 4 3
116 2 2 2 9 1 3 1 4 3
117 2 2 2 14 1 3 1 4 3
118 1 1 1 2 3 4 3
119 2 2 2 14 1 3 1 4
